\\n\\n
IntechOpen was founded by scientists, for scientists, in order to make book publishing accessible around the globe. Over the last two decades, this has driven Open Access (OA) book publishing whilst levelling the playing field for global academics. Through our innovative publishing model and the support of the research community, we have now published over 5,700 Open Access books and are visited online by over three million academics every month. These researchers are increasingly working in broad technology-based subjects, driving multidisciplinary academic endeavours into human health, environment, and technology.
\\n\\nBy listening to our community, and in order to serve these rapidly growing areas which lie at the core of IntechOpen's expertise, we are launching a portfolio of Open Science journals:
\\n\\nAll three journals will publish under an Open Access model and embrace Open Science policies to help support the changing needs of academics in these fast-moving research areas. There will be direct links to preprint servers and data repositories, allowing full reproducibility and rapid dissemination of published papers to help accelerate the pace of research. Each journal has renowned Editors in Chief who will work alongside a global Editorial Board, delivering robust single-blind peer review. Supported by our internal editorial teams, this will ensure our authors will receive a quick, user-friendly, and personalised publishing experience.
\\n\\n"By launching our journals portfolio we are introducing new, dedicated homes for interdisciplinary technology-focused researchers to publish their work, whilst embracing Open Science and creating a unique global home for academics to disseminate their work. We are taking a leap toward Open Science continuing and expanding our fundamental commitment to openly sharing scientific research across the world, making it available for the benefit of all." Dr. Sara Uhac, IntechOpen CEO
\\n\\n"Our aim is to promote and create better science for a better world by increasing access to information and the latest scientific developments to all scientists, innovators, entrepreneurs and students and give them the opportunity to learn, observe and contribute to knowledge creation. Open Science promotes a swifter path from research to innovation to produce new products and services." Alex Lazinica, IntechOpen founder
\\n\\nIn conclusion, Natalia Reinic Babic, Head of Journal Publishing and Open Science at IntechOpen adds:
\\n\\n“On behalf of the journal team I’d like to thank all our Editors in Chief, Editorial Boards, internal supporting teams, and our scientific community for their continuous support in making this portfolio a reality - we couldn’t have done it without you! With your support in place, we are confident these journals will become as impactful and successful as our book publishing program and bring us closer to a more open (science) future.”
\\n\\nWe invite you to visit the journals homepage and learn more about the journal’s Editorial Boards, scope and vision as all three journals are now open for submissions.
\\n\\nFeel free to share this news on social media and help us mark this memorable moment!
\\n\\n\\n"}]',published:!0,mainMedia:{caption:"",originalUrl:"/media/original/237"}},components:[{type:"htmlEditorComponent",content:'
After years of being acknowledged as the world's leading publisher of Open Access books, today, we are proud to announce we’ve successfully launched a portfolio of Open Science journals covering rapidly expanding areas of interdisciplinary research.
\n\n\n\nIntechOpen was founded by scientists, for scientists, in order to make book publishing accessible around the globe. Over the last two decades, this has driven Open Access (OA) book publishing whilst levelling the playing field for global academics. Through our innovative publishing model and the support of the research community, we have now published over 5,700 Open Access books and are visited online by over three million academics every month. These researchers are increasingly working in broad technology-based subjects, driving multidisciplinary academic endeavours into human health, environment, and technology.
\n\nBy listening to our community, and in order to serve these rapidly growing areas which lie at the core of IntechOpen's expertise, we are launching a portfolio of Open Science journals:
\n\nAll three journals will publish under an Open Access model and embrace Open Science policies to help support the changing needs of academics in these fast-moving research areas. There will be direct links to preprint servers and data repositories, allowing full reproducibility and rapid dissemination of published papers to help accelerate the pace of research. Each journal has renowned Editors in Chief who will work alongside a global Editorial Board, delivering robust single-blind peer review. Supported by our internal editorial teams, this will ensure our authors will receive a quick, user-friendly, and personalised publishing experience.
\n\n"By launching our journals portfolio we are introducing new, dedicated homes for interdisciplinary technology-focused researchers to publish their work, whilst embracing Open Science and creating a unique global home for academics to disseminate their work. We are taking a leap toward Open Science continuing and expanding our fundamental commitment to openly sharing scientific research across the world, making it available for the benefit of all." Dr. Sara Uhac, IntechOpen CEO
\n\n"Our aim is to promote and create better science for a better world by increasing access to information and the latest scientific developments to all scientists, innovators, entrepreneurs and students and give them the opportunity to learn, observe and contribute to knowledge creation. Open Science promotes a swifter path from research to innovation to produce new products and services." Alex Lazinica, IntechOpen founder
\n\nIn conclusion, Natalia Reinic Babic, Head of Journal Publishing and Open Science at IntechOpen adds:
\n\n“On behalf of the journal team I’d like to thank all our Editors in Chief, Editorial Boards, internal supporting teams, and our scientific community for their continuous support in making this portfolio a reality - we couldn’t have done it without you! With your support in place, we are confident these journals will become as impactful and successful as our book publishing program and bring us closer to a more open (science) future.”
\n\nWe invite you to visit the journals homepage and learn more about the journal’s Editorial Boards, scope and vision as all three journals are now open for submissions.
\n\nFeel free to share this news on social media and help us mark this memorable moment!
\n\n\n'}],latestNews:[{slug:"webinar-introduction-to-open-science-wednesday-18-may-1-pm-cest-20220518",title:"Webinar: Introduction to Open Science | Wednesday 18 May, 1 PM CEST"},{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"},{slug:"introducing-intechopen-book-series-a-new-publishing-format-for-oa-books-20210915",title:"Introducing IntechOpen Book Series - A New Publishing Format for OA Books"}]},book:{item:{type:"book",id:"9210",leadTitle:null,fullTitle:"Quantum Dots - Fundamental and Applications",title:"Quantum Dots",subtitle:"Fundamental and Applications",reviewType:"peer-reviewed",abstract:"Quantum dots (QDs) are luminescent semiconductor nanocrystals with unique chemical and physical properties due to their size and highly compact structure. QDs were first proposed for use in luminescent concentrators to replace organic dye molecules. In this book, the interest is in taking advantage of the emission properties of QDS, which can be tuned by their size, resulting from quantum confinement. In addition, the book discusses the potential of QDs as contrast and therapeutic agents in the field of medicine.",isbn:"978-1-83880-919-5",printIsbn:"978-1-83880-918-8",pdfIsbn:"978-1-83880-920-1",doi:"10.5772/intechopen.83206",price:100,priceEur:109,priceUsd:129,slug:"quantum-dots-fundamental-and-applications",numberOfPages:92,isOpenForSubmission:!1,isInWos:1,isInBkci:!1,hash:"a4343b3c941808702febf1d6b5bda803",bookSignature:"Faten Divsar",publishedDate:"June 24th 2020",coverURL:"https://cdn.intechopen.com/books/images_new/9210.jpg",numberOfDownloads:4654,numberOfWosCitations:7,numberOfCrossrefCitations:11,numberOfCrossrefCitationsByBook:1,numberOfDimensionsCitations:18,numberOfDimensionsCitationsByBook:2,hasAltmetrics:0,numberOfTotalCitations:36,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"May 29th 2019",dateEndSecondStepPublish:"September 20th 2019",dateEndThirdStepPublish:"November 19th 2019",dateEndFourthStepPublish:"February 7th 2020",dateEndFifthStepPublish:"April 7th 2020",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,7",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"293418",title:"Dr.",name:"Faten",middleName:null,surname:"Divsar",slug:"faten-divsar",fullName:"Faten Divsar",profilePictureURL:"https://mts.intechopen.com/storage/users/293418/images/system/293418.jpg",biography:"Faten Divsar received her PhD in analytical chemistry from Kharazmi University, Tehran in 2009. She conducted her postdoctoral training at Nanjing University (Nanjing, China) in 2011 and 2012, where her research was mainly devoted to the design of DNA biosensors by means of electrochemiluminescence spectrometry. Currently she is an Assistant Professor at the Chemistry Department of Payame Noor University, Iran. Her research focuses on two active programs, namely design of bioanalytical and electrochemical sensors, and development of innovative nanomaterials for pollution removal and water treatment.",institutionString:"Payame Noor University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Payame Noor University",institutionURL:null,country:{name:"Iran"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"208",title:"Material Science",slug:"nanotechnology-and-nanomaterials-material-science"}],chapters:[{id:"71780",title:"Introductory Chapter: Quantum Dots",doi:"10.5772/intechopen.92151",slug:"introductory-chapter-quantum-dots",totalDownloads:797,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Faten Divsar",downloadPdfUrl:"/chapter/pdf-download/71780",previewPdfUrl:"/chapter/pdf-preview/71780",authors:[{id:"293418",title:"Dr.",name:"Faten",surname:"Divsar",slug:"faten-divsar",fullName:"Faten Divsar"}],corrections:null},{id:"70534",title:"Quantum Confinement Effect of 2D Nanomaterials",doi:"10.5772/intechopen.90140",slug:"quantum-confinement-effect-of-2d-nanomaterials",totalDownloads:960,totalCrossrefCites:11,totalDimensionsCites:17,hasAltmetrics:0,abstract:"Quantum confinement is the spatial confinement of electron–hole pairs (excitons) in one or more dimensions within a material, and also electronic energy levels are discrete. It is due to the confinement of the electronic wave function to the physical dimensions of the particles. In this effect can be divided into three ways, 1D confinement (free carrier in a plane), quantum wells; 2D confinement (carriers are free to move down), quantum wire; and 3D confinement (carriers are confined in all directions), which are discussed in detail. In addition the formation mechanism of exciton and quantum confinement behavior of strong, moderate, and weak confinement have been discussed below.",signatures:"Gopal Ramalingam, Poopathy Kathirgamanathan, Ganesan Ravi, Thangavel Elangovan, Bojarajan Arjun kumar, Nadarajah Manivannan and Kaviyarasu Kasinathan",downloadPdfUrl:"/chapter/pdf-download/70534",previewPdfUrl:"/chapter/pdf-preview/70534",authors:[{id:"250055",title:"Dr.",name:"Elangovan",surname:"Thanagvel",slug:"elangovan-thanagvel",fullName:"Elangovan Thanagvel"},{id:"306901",title:"Dr.",name:"Ramalingam",surname:"Gopal",slug:"ramalingam-gopal",fullName:"Ramalingam Gopal"},{id:"307937",title:"Prof.",name:"Poopathy",surname:"Kathikamanagthan",slug:"poopathy-kathikamanagthan",fullName:"Poopathy Kathikamanagthan"},{id:"307938",title:"Prof.",name:"Ganasen",surname:"Ravi",slug:"ganasen-ravi",fullName:"Ganasen Ravi"},{id:"307939",title:"Mr.",name:"Bojarajan",surname:"Arjun Kumar",slug:"bojarajan-arjun-kumar",fullName:"Bojarajan Arjun Kumar"}],corrections:null},{id:"71659",title:"Temperature Effects in the Photoluminescence of Semiconductor Quantum Dots",doi:"10.5772/intechopen.91888",slug:"temperature-effects-in-the-photoluminescence-of-semiconductor-quantum-dots",totalDownloads:731,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"Temperature effects in the exciton photoluminescence specific to semiconductor quantum dots (QDs) are reviewed using Si QDs as an example. The processes of direct and indirect optical excitation of spatially confined excitons in quantum dots embedded in dielectric matrix are analyzed. The temperature behavior of the quantum dots photoluminescence (PL) excited by various methods was described in detail by a generalized electronic transitions scheme using different exciton relaxation models. The different types of temperature dependences were analyzed. The analytical expressions were obtained for their description, which allow one to determine the energy and kinetic characteristics of QD photoluminescence. It was found that the shape of the temperature dependence makes it possible to understand whether the process of exciton relaxation contains several different thermally activated stages or this is a simple one-stage process. The applicability of the obtained expressions for the analysis of the luminescence properties of quantum dots is demonstrated by the example of crystalline and amorphous silicon nanoclusters in silica matrix. It has been established that the quantum confinement effect of excitons in quantum dots leads to a decrease in the frequency characteristics and thermal activation barriers for nonradiative transitions.",signatures:"Anatoly Zatsepin and Dmitry Biryukov",downloadPdfUrl:"/chapter/pdf-download/71659",previewPdfUrl:"/chapter/pdf-preview/71659",authors:[{id:"230919",title:"Dr.",name:"Anatoly",surname:"Zatsepin",slug:"anatoly-zatsepin",fullName:"Anatoly Zatsepin"},{id:"312874",title:"Dr.",name:"Dmitry",surname:"Biryukov",slug:"dmitry-biryukov",fullName:"Dmitry Biryukov"}],corrections:null},{id:"70028",title:"Quantum Dots CdSe/ZnS as a Source Array of Entangled States",doi:"10.5772/intechopen.88558",slug:"quantum-dots-cdse-zns-as-a-source-array-of-entangled-states",totalDownloads:699,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"A quantum dot is a quantum system in classical space with unique characteristics, as a result of a large quantum limitation. The experimental results of this chapter substantiate the ability of quantum dots to play a key role in purely quantum processes, for example, teleportation of quantum objects, and the generation of macroscopic quantum gravity force and, of course, are a qubit in quantum computing. A quantum dot has the ability to capture (capture) a photo-induced charge carrier by a surface defect of its crystal structure and, thereby, create a second stable long-lived quantum state, which is a necessary requirement for a qubit. This ability puts a quantum dot out of competition with respect to many other quantum objects, like qubits, in terms of the simplicity and cheapness of their continuous generation in standard laboratory conditions. Quantum dots have received wide recognition because of their unique exciton luminescence characteristics; this chapter substantiates a fundamentally new area to use quantum dots in the development and study of both fundamental and applied physics.",signatures:"Anatolii Isaev",downloadPdfUrl:"/chapter/pdf-download/70028",previewPdfUrl:"/chapter/pdf-preview/70028",authors:[{id:"308135",title:"M.D.",name:"Anatolii",surname:"Isaev",slug:"anatolii-isaev",fullName:"Anatolii Isaev"}],corrections:null},{id:"71347",title:"Quantum Dot Light-Emitting Diode: Structure, Mechanism, and Preparation",doi:"10.5772/intechopen.91162",slug:"quantum-dot-light-emitting-diode-structure-mechanism-and-preparation",totalDownloads:1151,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:"Quantum dot light-emitting diode (QLED) attracted much attention for the next generation of display due to its advantages in high color saturation, tunable color emission, and high stability. Compared with traditional LED display, QLED display has advantages in flexible and robust application, which makes wearable and stretchable display possible in the future. In addition, QLED display is a self-emissive display, in which light is generated by individual subpixel, each subpixel can be individually controlled. Each subpixel in LED display is constituted by liquid crystal and color filter, which make LED display have lower power efficiency and less enhanced functionality. This chapter introduces the QLED based on the QLED structure and light-emitting mechanism of QLED. Then, a novel method for fabricating QLEDs, which is based on the ZnO nanoparticles (NPs) incorporated into QD nanoparticles, will be introduced. The QLED device was fabricated by all-solution processes, which make the QLED fabrication process more flexible and more suitable for industrialization. What is more, as QLED devices were planned to integrate into a display, all-solution fabrication processes also make printing QLED display device possible in the near future.",signatures:"Ning Tu",downloadPdfUrl:"/chapter/pdf-download/71347",previewPdfUrl:"/chapter/pdf-preview/71347",authors:[{id:"311315",title:"Dr.",name:"Ning",surname:"Tu",slug:"ning-tu",fullName:"Ning Tu"}],corrections:null},{id:"71984",title:"Retracted: What Did We Attain with Luminescent Quantum Dots?",doi:"10.5772/intechopen.92209",slug:"retracted-what-did-we-attain-with-luminescent-quantum-dots-",totalDownloads:320,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"Quantum dots (QDs) are practically nanoparticles, which are obtained by reducing sizes until they reach the order of nanometers. Their unique optical properties inspire scientists especially in medical sciences in applications such as tumor detection, cardiovascular imaging, and cancer targeting. Here, we first discuss scanning acoustic microscopy (SAM) results to evaluate the potential of SAM in the detection of lead-sulfide (PbS), graphene, and cadmium-telluride/cadmium sulfide (CdTe/CdS) quantum dot aggregates. The success of imaging quantum dots by SAM indicated the potential of SAM in monitoring the microenvironment of the disease and also the therapeutic effect of the drug-loaded QDs. Therefore, secondly we present confocal laser scanning microscopy results of graphene QDs engulfed in macrophages, which are in high numbers in the microenvironment of tumors, to evaluate the potential of graphene QDs in tumor targeting.",signatures:"Bukem Tanoren and Ali Eren Guzey",downloadPdfUrl:"/chapter/pdf-download/71984",previewPdfUrl:"/chapter/pdf-preview/71984",authors:[null],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:[{id:"65",label:"highly cited contributor"}]},relatedBooks:[{type:"book",id:"6408",title:"Novel Nanomaterials",subtitle:"Synthesis and Applications",isOpenForSubmission:!1,hash:"f3585d338d78e4d31c200d9991b03692",slug:"novel-nanomaterials-synthesis-and-applications",bookSignature:"George Z. Kyzas and Athanasios C. Mitropoulos",coverURL:"https://cdn.intechopen.com/books/images_new/6408.jpg",editedByType:"Edited by",editors:[{id:"152296",title:"Prof.",name:"George",surname:"Kyzas",slug:"george-kyzas",fullName:"George Kyzas"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6833",title:"Chemical Vapor Deposition for Nanotechnology",subtitle:null,isOpenForSubmission:!1,hash:"31d2b0b2a437691b6a657030687b0096",slug:"chemical-vapor-deposition-for-nanotechnology",bookSignature:"Pietro Mandracci",coverURL:"https://cdn.intechopen.com/books/images_new/6833.jpg",editedByType:"Edited by",editors:[{id:"80989",title:"Prof.",name:"Pietro",surname:"Mandracci",slug:"pietro-mandracci",fullName:"Pietro Mandracci"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7640",title:"Perspective of Carbon Nanotubes",subtitle:null,isOpenForSubmission:!1,hash:"8b85a9957fad5206369eadf0c1ffa27d",slug:"perspective-of-carbon-nanotubes",bookSignature:"Hosam El-Din Saleh and Said Moawad Mohamed El-Sheikh",coverURL:"https://cdn.intechopen.com/books/images_new/7640.jpg",editedByType:"Edited by",editors:[{id:"144691",title:"Prof.",name:"Hosam",surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8385",title:"Nanocrystalline Materials",subtitle:null,isOpenForSubmission:!1,hash:"cf72d957868565da82cc4ad919e6c4d7",slug:"nanocrystalline-materials",bookSignature:"Behrooz Movahedi",coverURL:"https://cdn.intechopen.com/books/images_new/8385.jpg",editedByType:"Edited by",editors:[{id:"150371",title:"Prof.",name:"Behrooz",surname:"Movahedi",slug:"behrooz-movahedi",fullName:"Behrooz Movahedi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6218",title:"Carbon Nanotubes",subtitle:"Recent Progress",isOpenForSubmission:!1,hash:"9f38af20209e9d816b7d57ecbba386b9",slug:"carbon-nanotubes-recent-progress",bookSignature:"Mohammed Muzibur Rahman and Abdullah Mohamed Asiri",coverURL:"https://cdn.intechopen.com/books/images_new/6218.jpg",editedByType:"Edited by",editors:[{id:"24438",title:"Prof.",name:"Mohammed Muzibur",surname:"Rahman",slug:"mohammed-muzibur-rahman",fullName:"Mohammed Muzibur Rahman"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6501",title:"Electrospinning Method Used to Create Functional Nanocomposites Films",subtitle:null,isOpenForSubmission:!1,hash:"c28620c5ccc64e4b32eb9758302a1679",slug:"electrospinning-method-used-to-create-functional-nanocomposites-films",bookSignature:"Tomasz Tański, Pawel Jarka and Wiktor Matysiak",coverURL:"https://cdn.intechopen.com/books/images_new/6501.jpg",editedByType:"Edited by",editors:[{id:"15700",title:"Prof.",name:"Tomasz Arkadiusz",surname:"Tański",slug:"tomasz-arkadiusz-tanski",fullName:"Tomasz Arkadiusz Tański"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7684",title:"Multilayer Thin Films",subtitle:"Versatile Applications for Materials Engineering",isOpenForSubmission:!1,hash:"fd04577df0c895320c3f06d98308ea67",slug:"multilayer-thin-films-versatile-applications-for-materials-engineering",bookSignature:"Sukumar Basu",coverURL:"https://cdn.intechopen.com/books/images_new/7684.jpg",editedByType:"Edited by",editors:[{id:"50632",title:"Prof.",name:"Sukumar",surname:"Basu",slug:"sukumar-basu",fullName:"Sukumar Basu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8446",title:"Zinc Oxide Based Nano Materials and Devices",subtitle:null,isOpenForSubmission:!1,hash:"7c1d14eb8eac769093f8d7a219a3884f",slug:"zinc-oxide-based-nano-materials-and-devices",bookSignature:"Ahmed M. Nahhas",coverURL:"https://cdn.intechopen.com/books/images_new/8446.jpg",editedByType:"Edited by",editors:[{id:"140058",title:"Prof.",name:"Ahmed",surname:"Nahhas",slug:"ahmed-nahhas",fullName:"Ahmed Nahhas"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6960",title:"Flame Retardants",subtitle:null,isOpenForSubmission:!1,hash:"506ea55aeb09b1a47f9113cc66594291",slug:"flame-retardants",bookSignature:"Fahmina Zafar and Eram Sharmin",coverURL:"https://cdn.intechopen.com/books/images_new/6960.jpg",editedByType:"Edited by",editors:[{id:"89672",title:"Dr.",name:"Fahmina",surname:"Zafar",slug:"fahmina-zafar",fullName:"Fahmina Zafar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7652",title:"Nanostructures",subtitle:null,isOpenForSubmission:!1,hash:"ad1e5c5f214960269e89371d1110cbc0",slug:"nanostructures",bookSignature:"Sadia Ameen, M. Shaheer Akhtar and Hyung-Shik Shin",coverURL:"https://cdn.intechopen.com/books/images_new/7652.jpg",editedByType:"Edited by",editors:[{id:"52613",title:"Dr.",name:"Sadia",surname:"Ameen",slug:"sadia-ameen",fullName:"Sadia Ameen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"80612",slug:"corrigendum-to-risk-assessment-and-health-safety-and-environmental-management-of-carbon-nanomaterial",title:"Corrigendum to: Risk Assessment and Health, Safety, and Environmental Management of Carbon Nanomaterials",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/80612.pdf",downloadPdfUrl:"/chapter/pdf-download/80612",previewPdfUrl:"/chapter/pdf-preview/80612",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/80612",risUrl:"/chapter/ris/80612",chapter:{id:"66689",slug:"risk-assessment-and-health-safety-and-environmental-management-of-carbon-nanomaterials",signatures:"Guilherme Lenz e Silva, Camila Viana, Danieli Domingues and Fernanda Vieira",dateSubmitted:null,dateReviewed:"February 26th 2019",datePrePublished:"April 11th 2019",datePublished:"February 19th 2020",book:{id:"8137",title:"Nanomaterials",subtitle:"Toxicity, Human Health and Environment",fullTitle:"Nanomaterials - Toxicity, Human Health and Environment",slug:"nanomaterials-toxicity-human-health-and-environment",publishedDate:"February 19th 2020",bookSignature:"Simona Clichici, Adriana Filip and Gustavo M. do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/8137.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"64160",title:"Prof.",name:"Simona",middleName:null,surname:"Clichici",slug:"simona-clichici",fullName:"Simona Clichici"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"251730",title:"Dr.",name:"Guilherme",middleName:"Fredeico Bernardo",surname:"Lenz E Silva",fullName:"Guilherme Lenz E Silva",slug:"guilherme-lenz-e-silva",email:"guilhermelenz@usp.br",position:null,institution:null},{id:"286148",title:"Dr.",name:"Camila",middleName:null,surname:"Viana",fullName:"Camila Viana",slug:"camila-viana",email:"camilaoviana@gmail.com",position:null,institution:null},{id:"286149",title:"Dr.",name:"Fernanda",middleName:null,surname:"Vieira",fullName:"Fernanda Vieira",slug:"fernanda-vieira",email:"fevieira2001@gmail.com",position:null,institution:null},{id:"286151",title:"M.Sc.",name:"Danieli",middleName:"Silva",surname:"Domingues",fullName:"Danieli Domingues",slug:"danieli-domingues",email:"danielisilva@ymail.com",position:null,institution:null}]}},chapter:{id:"66689",slug:"risk-assessment-and-health-safety-and-environmental-management-of-carbon-nanomaterials",signatures:"Guilherme Lenz e Silva, Camila Viana, Danieli Domingues and Fernanda Vieira",dateSubmitted:null,dateReviewed:"February 26th 2019",datePrePublished:"April 11th 2019",datePublished:"February 19th 2020",book:{id:"8137",title:"Nanomaterials",subtitle:"Toxicity, Human Health and Environment",fullTitle:"Nanomaterials - Toxicity, Human Health and Environment",slug:"nanomaterials-toxicity-human-health-and-environment",publishedDate:"February 19th 2020",bookSignature:"Simona Clichici, Adriana Filip and Gustavo M. do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/8137.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"64160",title:"Prof.",name:"Simona",middleName:null,surname:"Clichici",slug:"simona-clichici",fullName:"Simona Clichici"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"251730",title:"Dr.",name:"Guilherme",middleName:"Fredeico Bernardo",surname:"Lenz E Silva",fullName:"Guilherme Lenz E Silva",slug:"guilherme-lenz-e-silva",email:"guilhermelenz@usp.br",position:null,institution:null},{id:"286148",title:"Dr.",name:"Camila",middleName:null,surname:"Viana",fullName:"Camila Viana",slug:"camila-viana",email:"camilaoviana@gmail.com",position:null,institution:null},{id:"286149",title:"Dr.",name:"Fernanda",middleName:null,surname:"Vieira",fullName:"Fernanda Vieira",slug:"fernanda-vieira",email:"fevieira2001@gmail.com",position:null,institution:null},{id:"286151",title:"M.Sc.",name:"Danieli",middleName:"Silva",surname:"Domingues",fullName:"Danieli Domingues",slug:"danieli-domingues",email:"danielisilva@ymail.com",position:null,institution:null}]},book:{id:"8137",title:"Nanomaterials",subtitle:"Toxicity, Human Health and Environment",fullTitle:"Nanomaterials - Toxicity, Human Health and Environment",slug:"nanomaterials-toxicity-human-health-and-environment",publishedDate:"February 19th 2020",bookSignature:"Simona Clichici, Adriana Filip and Gustavo M. do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/8137.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"64160",title:"Prof.",name:"Simona",middleName:null,surname:"Clichici",slug:"simona-clichici",fullName:"Simona Clichici"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"7612",leadTitle:null,title:"Electrospinning and Electrospraying",subtitle:"Techniques and Applications",reviewType:"peer-reviewed",abstract:"This book focuses on the recent advancements in the process parameters, research, and applications of electrospinning and electrospraying. The first chapter introduces the techniques and the effect of the parameters on the morphology of the nanofiber and nanoparticles and then the subsequent chapters focus on the applications of these techniques in different areas. This book will attract a broad audience including postgraduate students and industrial and academic investigators in sciences and engineering who wish to enhance their understanding of the emerging technologies and use this book as reference.",isbn:"978-1-78984-701-7",printIsbn:"978-1-78984-700-0",pdfIsbn:"978-1-83968-113-4",doi:"10.5772/intechopen.77414",price:119,priceEur:129,priceUsd:155,slug:"electrospinning-and-electrospraying-techniques-and-applications",numberOfPages:120,isOpenForSubmission:!1,isSalesforceBook:!1,hash:"77e9708250507395a4bea2c17d012982",bookSignature:"Sajjad Haider and Adnan Haider",publishedDate:"December 11th 2019",coverURL:"https://cdn.intechopen.com/books/images_new/7612.jpg",keywords:null,numberOfDownloads:5104,numberOfWosCitations:13,numberOfCrossrefCitations:11,numberOfDimensionsCitations:19,numberOfTotalCitations:43,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"November 8th 2018",dateEndSecondStepPublish:"January 17th 2019",dateEndThirdStepPublish:"March 18th 2019",dateEndFourthStepPublish:"May 23rd 2019",dateEndFifthStepPublish:"June 22nd 2019",remainingDaysToSecondStep:"3 years",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:"Edited by",kuFlag:!1,biosketch:null,coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"110708",title:"Dr.",name:"Sajjad",middleName:null,surname:"Haider",slug:"sajjad-haider",fullName:"Sajjad Haider",profilePictureURL:"https://mts.intechopen.com/storage/users/110708/images/system/110708.png",biography:"Dr. Sajjad Haider is an Associate Professor in the Department of Chemical Engineering, King Saud University, Riyadh, Saudi Arabia. He received his MSc in 1999 and M Phil in 2004 from the Institute of Chemical Sciences, University of Peshawar, KPK, Pakistan, and his Ph.D. degree in 2009 from the Department of Polymer Science and Engineering, Kyungpook National University, Taegu, South Korea. His research focuses on electrospun nanofibers, biopolymer composite, metal oxide/polymer composites, and polymer hydrogels to develop scaffolds for tissue engineering, drug delivery, and water treatment applications.",institutionString:"King Saud University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"5",institution:{name:"King Saud University",institutionURL:null,country:{name:"Saudi Arabia"}}}],coeditorOne:{id:"186100",title:"Dr.",name:"Adnan",middleName:null,surname:"Haider",slug:"adnan-haider",fullName:"Adnan Haider",profilePictureURL:"https://mts.intechopen.com/storage/users/186100/images/system/186100.jpg",biography:"Dr. Adnan Haider is an assistant professor at the Department of Chemistry, Kohat University of Science and Technology. He received his MSc degree in 2010 from the Kohat University of Science and Technology, KPK, Pakistan; PhD degree in 2016 from the Department of Polymer Science and Engineering, Kyungpook National University, Daegu, South Korea; and postdoctoral research in 2017 from the Department of Nano, Medical and Polymer Materials, School of Chemical Engineering, Yeungnam University, South Korea. His research work focuses on the development of scaffolds using polymer hydrogel and electrospun nanofibers for biomedical (tissue regeneration and drug delivery) and environmental applications.",institutionString:"Kohat University of Science and Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:null},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1169",title:"Condensed Matter Physics",slug:"nanotechnology-and-nanomaterials-material-science-condensed-matter-physics"}],chapters:[{id:"70029",title:"Electrohydrodynamic Processes and Their Affecting Parameters",slug:"electrohydrodynamic-processes-and-their-affecting-parameters",totalDownloads:843,totalCrossrefCites:1,authors:[{id:"110708",title:"Dr.",name:"Sajjad",surname:"Haider",slug:"sajjad-haider",fullName:"Sajjad Haider"}]},{id:"66975",title:"Electrospinning and Drug Delivery",slug:"electrospinning-and-drug-delivery",totalDownloads:1075,totalCrossrefCites:7,authors:[{id:"246279",title:"Associate Prof.",name:"Marilena",surname:"Vlachou",slug:"marilena-vlachou",fullName:"Marilena Vlachou"},{id:"246280",title:"Dr.",name:"Angeliki",surname:"Siamidi",slug:"angeliki-siamidi",fullName:"Angeliki Siamidi"},{id:"298461",title:"Mrs.",name:"Sotiria",surname:"Kyriakou",slug:"sotiria-kyriakou",fullName:"Sotiria Kyriakou"}]},{id:"68337",title:"Preparation, Characterization, and Applications of Electrospun Carbon Nanofibers and Its Composites",slug:"preparation-characterization-and-applications-of-electrospun-carbon-nanofibers-and-its-composites",totalDownloads:1216,totalCrossrefCites:1,authors:[{id:"247532",title:"Prof.",name:"Kim",surname:"Ick Soo",slug:"kim-ick-soo",fullName:"Kim Ick Soo"}]},{id:"67100",title:"Effect of Spray-Drying and Electrospraying as Drying Techniques on Lysozyme Characterisation",slug:"effect-of-spray-drying-and-electrospraying-as-drying-techniques-on-lysozyme-characterisation",totalDownloads:1062,totalCrossrefCites:1,authors:[{id:"136133",title:"Dr.",name:"Amal Ali",surname:"Elkordy",slug:"amal-ali-elkordy",fullName:"Amal Ali Elkordy"},{id:"291117",title:"Mrs.",name:"Ijeoma",surname:"Abraham",slug:"ijeoma-abraham",fullName:"Ijeoma Abraham"},{id:"299419",title:"Dr.",name:"Eman Ali",surname:"Elkordy",slug:"eman-ali-elkordy",fullName:"Eman Ali Elkordy"},{id:"299420",title:"Dr.",name:"Rita",surname:"Haj Ahmad",slug:"rita-haj-ahmad",fullName:"Rita Haj Ahmad"},{id:"299421",title:"Prof.",name:"Zeeshan",surname:"Ahmad",slug:"zeeshan-ahmad",fullName:"Zeeshan Ahmad"}]},{id:"66665",title:"Using the iESP Installed on the Space Station Moving in an Irregular Gravitational Field of the Asteroids Eros and Gaspra",slug:"using-the-iesp-installed-on-the-space-station-moving-in-an-irregular-gravitational-field-of-the-aste",totalDownloads:908,totalCrossrefCites:1,authors:[{id:"287645",title:"Prof.",name:"Olga",surname:"Starinova",slug:"olga-starinova",fullName:"Olga Starinova"},{id:"288983",title:"Mr.",name:"Andrey",surname:"Shornikov",slug:"andrey-shornikov",fullName:"Andrey Shornikov"},{id:"288985",title:"Mrs.",name:"Elizaveta",surname:"Nikolaeva",slug:"elizaveta-nikolaeva",fullName:"Elizaveta Nikolaeva"}]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"225753",firstName:"Marina",lastName:"Dusevic",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/225753/images/7224_n.png",email:"marina.d@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"5429",title:"Electrospinning",subtitle:"Material, Techniques, and Biomedical Applications",isOpenForSubmission:!1,hash:"ce8f54e9951bc68943c45e2b1622f02d",slug:"electrospinning-material-techniques-and-biomedical-applications",bookSignature:"Sajjad Haider and Adnan Haider",coverURL:"https://cdn.intechopen.com/books/images_new/5429.jpg",editedByType:"Edited by",editors:[{id:"110708",title:"Dr.",name:"Sajjad",surname:"Haider",slug:"sajjad-haider",fullName:"Sajjad Haider"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6241",title:"Hydrogels",subtitle:null,isOpenForSubmission:!1,hash:"b3a944044e8aecbba3bd88fba1bef0b1",slug:"hydrogels",bookSignature:"Sajjad Haider and Adnan Haider",coverURL:"https://cdn.intechopen.com/books/images_new/6241.jpg",editedByType:"Edited by",editors:[{id:"110708",title:"Dr.",name:"Sajjad",surname:"Haider",slug:"sajjad-haider",fullName:"Sajjad Haider"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10259",title:"Energy Storage Battery Systems",subtitle:"Fundamentals and Applications",isOpenForSubmission:!1,hash:"79ba911ac0fe448019d286a56e8b96c4",slug:"energy-storage-battery-systems-fundamentals-and-applications",bookSignature:"Sajjad Haider, Adnan Haider, Mehdi Khodaei and Liang Chen",coverURL:"https://cdn.intechopen.com/books/images_new/10259.jpg",editedByType:"Edited by",editors:[{id:"110708",title:"Dr.",name:"Sajjad",surname:"Haider",slug:"sajjad-haider",fullName:"Sajjad Haider"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10412",title:"Transition Metal Compounds",subtitle:"Synthesis, Properties, and Application",isOpenForSubmission:!1,hash:"bd7287b801dc0ac77e01f66842dc1d99",slug:"transition-metal-compounds-synthesis-properties-and-application",bookSignature:"Sajjad Haider and Adnan Haider",coverURL:"https://cdn.intechopen.com/books/images_new/10412.jpg",editedByType:"Edited by",editors:[{id:"110708",title:"Dr.",name:"Sajjad",surname:"Haider",slug:"sajjad-haider",fullName:"Sajjad Haider"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3621",title:"Silver Nanoparticles",subtitle:null,isOpenForSubmission:!1,hash:null,slug:"silver-nanoparticles",bookSignature:"David Pozo Perez",coverURL:"https://cdn.intechopen.com/books/images_new/3621.jpg",editedByType:"Edited by",editors:[{id:"6667",title:"Dr.",name:"David",surname:"Pozo",slug:"david-pozo",fullName:"David Pozo"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"397",title:"Nanofibers",subtitle:"Production, Properties and Functional Applications",isOpenForSubmission:!1,hash:"934fe33b73b2ecba961c67d5a90021ec",slug:"nanofibers-production-properties-and-functional-applications",bookSignature:"Tong Lin",coverURL:"https://cdn.intechopen.com/books/images_new/397.jpg",editedByType:"Edited by",editors:[{id:"49937",title:"Dr.",name:"Tong",surname:"Lin",slug:"tong-lin",fullName:"Tong Lin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1045",title:"Nanocomposites and Polymers with Analytical Methods",subtitle:null,isOpenForSubmission:!1,hash:"65d477e855685ea85913e5aba0c5217e",slug:"nanocomposites-and-polymers-with-analytical-methods",bookSignature:"John Cuppoletti",coverURL:"https://cdn.intechopen.com/books/images_new/1045.jpg",editedByType:"Edited by",editors:[{id:"49991",title:"Dr.",name:"John",surname:"Cuppoletti",slug:"john-cuppoletti",fullName:"John Cuppoletti"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3200",title:"Nanofibers",subtitle:null,isOpenForSubmission:!1,hash:"97487143b896780afaf08cfd67cd1eec",slug:"nanofibers",bookSignature:"Ashok Kumar",coverURL:"https://cdn.intechopen.com/books/images_new/3200.jpg",editedByType:"Edited by",editors:[{id:"7718",title:"Professor",name:"Ashok",surname:"Kumar",slug:"ashok-kumar",fullName:"Ashok Kumar"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"191",title:"Advances in Nanocomposite Technology",subtitle:null,isOpenForSubmission:!1,hash:"4dc3407e602cdd348af663727baebe3d",slug:"advances-in-nanocomposite-technology",bookSignature:"Abbass Hashim",coverURL:"https://cdn.intechopen.com/books/images_new/191.jpg",editedByType:"Edited by",editors:[{id:"6700",title:"Dr.",name:"Abbass A.",surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3077",title:"Syntheses and Applications of Carbon Nanotubes and Their Composites",subtitle:null,isOpenForSubmission:!1,hash:"38dd4fb088a27b2552bf3d371e8c2872",slug:"syntheses-and-applications-of-carbon-nanotubes-and-their-composites",bookSignature:"Satoru Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/3077.jpg",editedByType:"Edited by",editors:[{id:"30519",title:"Dr.",name:"Satoru",surname:"Suzuki",slug:"satoru-suzuki",fullName:"Satoru Suzuki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"36789",title:"Using Grid Computing for Constructing Ternary Covering Arrays",doi:"10.5772/36019",slug:"using-grid-computing-for-constructing-ternary-covering-arrays",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/36789.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/36789",previewPdfUrl:"/chapter/pdf-preview/36789",totalDownloads:2149,totalViews:114,totalCrossrefCites:0,totalDimensionsCites:0,totalAltmetricsMentions:0,impactScore:0,impactScorePercentile:13,impactScoreQuartile:1,hasAltmetrics:0,dateSubmitted:"May 18th 2011",dateReviewed:"October 30th 2011",datePrePublished:null,datePublished:"May 16th 2012",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/36789",risUrl:"/chapter/ris/36789",book:{id:"1865",slug:"grid-computing-technology-and-applications-widespread-coverage-and-new-horizons"},signatures:"Himer Avila-George, Jose Torres-Jimenez, Abel Carrión and Vicente Hernández",authors:[{id:"106782",title:"Dr.",name:"Himer",middleName:null,surname:"Avila-George",fullName:"Himer Avila-George",slug:"himer-avila-george",email:"hiavgeo@posgrado.upv.es",position:"Coordinación de TICs",profilePictureURL:"https://mts.intechopen.com/storage/users/106782/images/2209_n.jpg",institution:null},{id:"138115",title:"Dr.",name:"Jose",middleName:null,surname:"Torres-Jimenez",fullName:"Jose Torres-Jimenez",slug:"jose-torres-jimenez",email:"jtj@cinvestav.mx",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:null},{id:"138249",title:"MSc.",name:"Abel",middleName:null,surname:"Carrión",fullName:"Abel Carrión",slug:"abel-carrion",email:"abcarcol@fiv.upv.es",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:null},{id:"138250",title:"Dr.",name:"Vicente",middleName:null,surname:"Hernández",fullName:"Vicente Hernández",slug:"vicente-hernandez",email:"vhernandez@dsic.upv.es",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:null}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"1865",type:"book",title:"Grid Computing",subtitle:"Technology and Applications, Widespread Coverage and New Horizons",fullTitle:"Grid Computing - Technology and Applications, Widespread Coverage and New Horizons",slug:"grid-computing-technology-and-applications-widespread-coverage-and-new-horizons",publishedDate:"May 16th 2012",bookSignature:"Soha Maad",coverURL:"https://cdn.intechopen.com/books/images_new/1865.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:null,printIsbn:"978-953-51-0604-3",pdfIsbn:"978-953-51-5617-8",reviewType:"peer-reviewed",numberOfWosCitations:7,isAvailableForWebshopOrdering:!0,editors:[{id:"7692",title:"Dr.",name:"Soha",middleName:null,surname:"Maad",slug:"soha-maad",fullName:"Soha Maad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"614"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"36780",type:"chapter",title:"w-TG: A Combined Algorithm to Optimize the Runtime of the Grid-Based Workflow Within an SLA Context",slug:"w-tg-a-combined-algorithm-to-optimize-the-runtime-of-the-grid-based-workflow-within-an-sla-context",totalDownloads:1549,totalCrossrefCites:0,signatures:"Dang Minh Quan, Joern Altmann and Laurence T. Yang",reviewType:"peer-reviewed",authors:[{id:"106406",title:"Dr.",name:"Minh Quan",middleName:null,surname:"Dang",fullName:"Minh Quan Dang",slug:"minh-quan-dang"}]},{id:"36781",type:"chapter",title:"On the Effect of Applying the Task Clustering for Identical Processor Utilization to Heterogeneous Systems",slug:"on-the-effect-of-applying-the-task-clustering-for-identical-processor-utilization-to-heterogeneous-s",totalDownloads:1142,totalCrossrefCites:3,signatures:"Hidehiro Kanemitsu, Gilhyon Lee, Hidenori Nakazato, Takashige Hoshiai and Yoshiyori Urano",reviewType:"peer-reviewed",authors:[{id:"106066",title:"Dr.",name:"Hidehiro",middleName:null,surname:"Kanemitsu",fullName:"Hidehiro Kanemitsu",slug:"hidehiro-kanemitsu"},{id:"112197",title:"Mr.",name:"Gilhyon",middleName:null,surname:"Lee",fullName:"Gilhyon Lee",slug:"gilhyon-lee"},{id:"112198",title:"Prof.",name:"Hidenori",middleName:null,surname:"Nakazato",fullName:"Hidenori Nakazato",slug:"hidenori-nakazato"},{id:"112200",title:"Dr.",name:"Takashige",middleName:null,surname:"Hoshiai",fullName:"Takashige Hoshiai",slug:"takashige-hoshiai"},{id:"112201",title:"Prof.",name:"Yoshiyori",middleName:null,surname:"Urano",fullName:"Yoshiyori Urano",slug:"yoshiyori-urano"}]},{id:"36782",type:"chapter",title:"Resource Management for Data Intensive Tasks on Grids",slug:"resource-management-for-data-intensive-tasks-on-grids",totalDownloads:1467,totalCrossrefCites:0,signatures:"Imran Ahmad and Shikharesh Majumdar",reviewType:"peer-reviewed",authors:[{id:"104992",title:"Dr.",name:"Imran",middleName:null,surname:"Ahmad",fullName:"Imran Ahmad",slug:"imran-ahmad"},{id:"113848",title:"Prof.",name:"Shikharesh",middleName:null,surname:"Shikharesh Majumdar",fullName:"Shikharesh Shikharesh Majumdar",slug:"shikharesh-shikharesh-majumdar"}]},{id:"36783",type:"chapter",title:"A New Approach to Resource Discovery in Grid Computing",slug:"a-new-approach-to-resource-discovery-in-grid-computing",totalDownloads:2492,totalCrossrefCites:0,signatures:"Leyli Mohammad Khanli, Saeed Kargar and Ali Kazemi Niari",reviewType:"peer-reviewed",authors:[{id:"106343",title:"Dr.",name:"Leyli",middleName:null,surname:"Mohammad Khanli",fullName:"Leyli Mohammad Khanli",slug:"leyli-mohammad-khanli"},{id:"147346",title:"MSc.",name:"Saeed",middleName:null,surname:"Kargar",fullName:"Saeed Kargar",slug:"saeed-kargar"}]},{id:"36784",type:"chapter",title:"Task Scheduling in Grid Environment Using Simulated Annealing and Genetic Algorithm",slug:"minimizing-makespan-in-grid-environment-using-simulated-annealing-and-genetic-algorithm",totalDownloads:2554,totalCrossrefCites:2,signatures:"Wael Abdulal, Ahmad Jabas, S. Ramachandram and Omar Al Jadaan",reviewType:"peer-reviewed",authors:[{id:"103952",title:"Mr.",name:"Wael",middleName:null,surname:"Abdulal",fullName:"Wael Abdulal",slug:"wael-abdulal"},{id:"149175",title:"Prof.",name:"Ramachandram",middleName:null,surname:"Sirandas",fullName:"Ramachandram Sirandas",slug:"ramachandram-sirandas"}]},{id:"36785",type:"chapter",title:"Efficient Parallel Application Execution on Opportunistic Desktop Grids",slug:"efficient-parallel-application-execution-on-opportunistic-desktop-grids",totalDownloads:1782,totalCrossrefCites:1,signatures:"Francisco Silva, Fabio Kon, Daniel Batista, Alfredo Goldman, Fabio Costa and Raphael Camargo",reviewType:"peer-reviewed",authors:[{id:"105124",title:"Prof.",name:"Francisco José",middleName:null,surname:"Da Silva E Silva",fullName:"Francisco José Da Silva E Silva",slug:"francisco-jose-da-silva-e-silva"},{id:"113707",title:"Prof.",name:"Fabio",middleName:null,surname:"Kon",fullName:"Fabio Kon",slug:"fabio-kon"},{id:"113709",title:"Prof.",name:"Fabio",middleName:null,surname:"Costa",fullName:"Fabio Costa",slug:"fabio-costa"},{id:"113710",title:"Prof.",name:"Raphael",middleName:null,surname:"Camargo",fullName:"Raphael Camargo",slug:"raphael-camargo"},{id:"113712",title:"Prof.",name:"Daniel",middleName:null,surname:"Batista",fullName:"Daniel Batista",slug:"daniel-batista"},{id:"127903",title:"Prof.",name:"Alfredo",middleName:null,surname:"Goldman",fullName:"Alfredo Goldman",slug:"alfredo-goldman"}]},{id:"36786",type:"chapter",title:"Research and Implementation of Parallel Cache Model Through Grid Memory",slug:"research-and-implementation-of-parallel-cache-model-through-grid-memory",totalDownloads:1511,totalCrossrefCites:0,signatures:"Qingkui Chen, Lichun Na, He Jia, Song Lin Zhuang and Xiaodong Ding",reviewType:"peer-reviewed",authors:[{id:"110692",title:"Dr.",name:"Qingkui",middleName:null,surname:"Chen",fullName:"Qingkui Chen",slug:"qingkui-chen"},{id:"147355",title:"Dr.",name:"He",middleName:null,surname:"Jia",fullName:"He Jia",slug:"he-jia"}]},{id:"36787",type:"chapter",title:"Hierarchy-Aware Message-Passing in the Upcoming Many-Core Era",slug:"hierarchy-aware-message-passing-in-the-upcoming-many-core-era",totalDownloads:2247,totalCrossrefCites:0,signatures:"Carsten Clauss, Simon Pickartz, Stefan Lankes and Thomas Bemmerl",reviewType:"peer-reviewed",authors:[{id:"108932",title:"Dr.",name:"Carsten",middleName:null,surname:"Clauss",fullName:"Carsten Clauss",slug:"carsten-clauss"},{id:"113718",title:"Dr.",name:"Stefan",middleName:null,surname:"Lankes",fullName:"Stefan Lankes",slug:"stefan-lankes"},{id:"113722",title:"Prof.",name:"Thomas",middleName:null,surname:"Bemmerl",fullName:"Thomas Bemmerl",slug:"thomas-bemmerl"},{id:"137686",title:"BSc.",name:"Simon",middleName:null,surname:"Pickartz",fullName:"Simon Pickartz",slug:"simon-pickartz"}]},{id:"36788",type:"chapter",title:"Grid Computing in High Energy Physics Experiments",slug:"grid-computing-in-high-energy-physics-experiments",totalDownloads:1809,totalCrossrefCites:0,signatures:"Dagmar Adamová and Pablo Saiz",reviewType:"peer-reviewed",authors:[{id:"107786",title:"Dr.",name:"Dagmar",middleName:null,surname:"Adamova",fullName:"Dagmar Adamova",slug:"dagmar-adamova"},{id:"138329",title:"Dr.",name:"Pablo",middleName:null,surname:"Saiz",fullName:"Pablo Saiz",slug:"pablo-saiz"}]},{id:"36789",type:"chapter",title:"Using Grid Computing for Constructing Ternary Covering Arrays",slug:"using-grid-computing-for-constructing-ternary-covering-arrays",totalDownloads:2149,totalCrossrefCites:0,signatures:"Himer Avila-George, Jose Torres-Jimenez, Abel Carrión and Vicente Hernández",reviewType:"peer-reviewed",authors:[{id:"106782",title:"Dr.",name:"Himer",middleName:null,surname:"Avila-George",fullName:"Himer Avila-George",slug:"himer-avila-george"},{id:"138115",title:"Dr.",name:"Jose",middleName:null,surname:"Torres-Jimenez",fullName:"Jose Torres-Jimenez",slug:"jose-torres-jimenez"},{id:"138249",title:"MSc.",name:"Abel",middleName:null,surname:"Carrión",fullName:"Abel Carrión",slug:"abel-carrion"},{id:"138250",title:"Dr.",name:"Vicente",middleName:null,surname:"Hernández",fullName:"Vicente Hernández",slug:"vicente-hernandez"}]},{id:"36790",type:"chapter",title:"Grid Infrastructure for Domain Decomposition Methods in Computational ElectroMagnetics",slug:"grid-infrastructure-for-domain-decomposition-methods-in-computational-electromagnetics",totalDownloads:1736,totalCrossrefCites:2,signatures:"Olivier Terzo, Pietro Ruiu, Lorenzo Mossucca, Matteo Alessandro Francavilla and Francesca Vipiana",reviewType:"peer-reviewed",authors:[{id:"109381",title:"Dr.",name:"Olivier",middleName:null,surname:"Terzo",fullName:"Olivier Terzo",slug:"olivier-terzo"},{id:"111672",title:"Dr.",name:"Francesca",middleName:null,surname:"Vipiana",fullName:"Francesca Vipiana",slug:"francesca-vipiana"},{id:"111673",title:"Dr.",name:"Matteo Alessandro",middleName:null,surname:"Francavilla",fullName:"Matteo Alessandro Francavilla",slug:"matteo-alessandro-francavilla"},{id:"111674",title:"Dr.",name:"Lorenzo",middleName:null,surname:"Mossucca",fullName:"Lorenzo Mossucca",slug:"lorenzo-mossucca"},{id:"111681",title:"Dr.",name:"Pietro",middleName:null,surname:"Ruiu",fullName:"Pietro Ruiu",slug:"pietro-ruiu"}]},{id:"36791",type:"chapter",title:"Characterization of Hepatic Lesions Using Grid Computing (Globus) and Neural Networks",slug:"characterization-of-hepatic-lesions-using-grid-computing-globus-and-neural-networks",totalDownloads:1725,totalCrossrefCites:0,signatures:"Sheng Hung Chung and Ean Teng Khor",reviewType:"peer-reviewed",authors:[{id:"113164",title:"Dr.",name:"Shenghung",middleName:null,surname:"Chung",fullName:"Shenghung Chung",slug:"shenghung-chung"},{id:"113498",title:"Dr.",name:"Ean",middleName:null,surname:"Teng",fullName:"Ean Teng",slug:"ean-teng"}]},{id:"36792",type:"chapter",title:"Applications Exploiting e-Infrastructures Across Europe and India Within the EU-IndiaGrid Project",slug:"applications-exploiting-e-infrastructures-across-europe-and-india-within-the-eu-india-grid-project",totalDownloads:2125,totalCrossrefCites:0,signatures:"Alberto Masoni and Stefano Cozzini",reviewType:"peer-reviewed",authors:[{id:"114545",title:"Dr.",name:"Alberto",middleName:null,surname:"Masoni",fullName:"Alberto Masoni",slug:"alberto-masoni"},{id:"115480",title:"Dr.",name:"Stefano",middleName:null,surname:"Cozzini",fullName:"Stefano Cozzini",slug:"stefano-cozzini"}]},{id:"36793",type:"chapter",title:"Open Development Platform for Embedded Systems",slug:"open-development-platform-for-embedded-systems",totalDownloads:3059,totalCrossrefCites:0,signatures:"E. Ostúa, A. Muñoz, P. Ruiz-de-Clavijo, M.J. Bellido, D. Guerrero and A. Millán",reviewType:"peer-reviewed",authors:[{id:"114135",title:"MSc.",name:"Enrique",middleName:null,surname:"Ostua",fullName:"Enrique Ostua",slug:"enrique-ostua"},{id:"147933",title:"MSc.",name:"Alejandro",middleName:null,surname:"Muñoz",fullName:"Alejandro Muñoz",slug:"alejandro-munoz"},{id:"147934",title:"Dr.",name:"Paulino",middleName:null,surname:"Ruiz-De-Clavijo",fullName:"Paulino Ruiz-De-Clavijo",slug:"paulino-ruiz-de-clavijo"},{id:"147935",title:"Prof.",name:"Manuel J.",middleName:null,surname:"Bellido",fullName:"Manuel J. Bellido",slug:"manuel-j.-bellido"},{id:"147936",title:"Dr.",name:"David",middleName:null,surname:"Guerrero",fullName:"David Guerrero",slug:"david-guerrero"},{id:"147937",title:"Dr.",name:"Alejandro",middleName:null,surname:"Millan",fullName:"Alejandro Millan",slug:"alejandro-millan"}]},{id:"36794",type:"chapter",title:"Potential of Grid Technology for Embedded Systems and Applications",slug:"potential-of-grid-technology-for-embedded-systems-and-applications",totalDownloads:2329,totalCrossrefCites:0,signatures:"Mona Abo El-Dahb and Yoichi Shiraishi",reviewType:"peer-reviewed",authors:[{id:"117774",title:"Dr.",name:"Mona",middleName:null,surname:"Abo El-Dahb",fullName:"Mona Abo El-Dahb",slug:"mona-abo-el-dahb"},{id:"151082",title:"Prof.",name:"Shiraishi",middleName:null,surname:"Yoichi",fullName:"Shiraishi Yoichi",slug:"shiraishi-yoichi"}]}]},relatedBooks:[{type:"book",id:"5113",title:"Augmented Reality",subtitle:null,isOpenForSubmission:!1,hash:"954d173e8f2d779038eab3d42ef6b159",slug:"augmented-reality",bookSignature:"Soha Maad",coverURL:"https://cdn.intechopen.com/books/images_new/5113.jpg",editedByType:"Edited by",editors:[{id:"7692",title:"Dr.",name:"Soha",surname:"Maad",slug:"soha-maad",fullName:"Soha Maad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"6756",title:"Coordinated and Multiple Data Views in Augmented Reality Environment",slug:"coordinated-and-multiple-data-views-in-augmented-reality-environment",signatures:"Bianchi Serique Meiguins, Aruanda Simões Gonçalves Meiguins, Leandro Hernadez Almeida, Rodrigo Augusto de Moraes Lourenço and Sergio Clayton Vianna Pinheiro",authors:[null]},{id:"6757",title:"Probeless Illumination Estimation for Outdoor Augmented Reality",slug:"probeless-illumination-estimation-for-outdoor-augmented-reality",signatures:"Madsen and Lal",authors:[null]},{id:"6758",title:"Design of Embedded Augmented Reality Systems",slug:"design-of-embedded-augmented-reality-systems",signatures:"J. Toledo, J. J. Martínez, J. Garrigós, R. Toledo-Moreo and J. M. Ferrández",authors:[null]},{id:"6759",title:"A Virtual Harp for Therapy in an Augmented Reality Environment",slug:"a-virtual-harp-for-therapy-in-an-augmented-reality-environment",signatures:"Tanasha Taylor and Shana Smith",authors:[null]},{id:"6760",title:"Augmented Reality for Minimally Invasive Surgery: Overview and Some Recent Advances",slug:"augmented-reality-for-minimally-invasive-surgery-overview-and-some-recent-advances",signatures:"Pablo Lamata, Wajid Ali, Alicia Cano, Jordi Cornella, Jerome Declerck, Ole J. Elle, Adinda Freudenthal, Hugo Furtado, Denis Kalkofen, Edvard Naerum, Eigil Samset, Patricia Sánchez-Gonzalez, Francisco M. Sánchez-Margallo, Dieter Schmalstieg, Mauro Sette, Thomas Stüdeli, Jos Vander Sloten and Enrique J. Gómez",authors:[null]},{id:"6761",title:"Using Augmented Reality to Cognitively Facilitate Product Assembly Process",slug:"using-augmented-reality-to-cognitively-facilitate-product-assembly-process",signatures:"Lei Hou and Xiangyu Wang",authors:[null]},{id:"6762",title:"Tangible Interfaces for Augmented Engineering Data Management",slug:"tangible-interfaces-for-augmented-engineering-data-management",signatures:"Michele Fiorentino, Giuseppe Monno and Antonio E. Uva",authors:[null]},{id:"6763",title:"Human Factor Guideline for Applying AR-based Manuals in Industry",slug:"human-factor-guideline-for-applying-ar-based-manuals-in-industry",signatures:"Miwa Nakanishi",authors:[null]},{id:"6764",title:"AAM and Non-rigid Registration in Augmented Reality",slug:"aam-and-non-rigid-registration-in-augmented-reality",signatures:"Yuan Tian, Tao Guan and Cheng Wang",authors:[null]},{id:"6765",title:"Augmented Reality Applied to Card Games",slug:"augmented-reality-applied-to-card-games",signatures:"Hidehiko Okada and Hiroki Arakawa",authors:[null]},{id:"6766",title:"Visualization Based on Geographic Information in Augmented Reality",slug:"visualization-based-on-geographic-information-in-augmented-reality",signatures:"Kikuo Asai",authors:[null]},{id:"6767",title:"Virtual and Augmented Reality in Finance: State Visibility of Events and Risk",slug:"virtual-and-augmented-reality-in-finance-state-visibility-of-events-and-risk",signatures:"Soha Maad, Samir Garbaya, JB McCarthy, Meurig Beynon, Saida Bouakaz and Rajagopal Nagarajan",authors:[null]},{id:"6768",title:"Augmented Reality for Multi-disciplinary Collaboration",slug:"augmented-reality-for-multi-disciplinary-collaboration",signatures:"Rui(Irene) Chen and Xiangyu Wang",authors:[null]}]}],publishedBooks:[{type:"book",id:"10",title:"Coherence and Ultrashort Pulse Laser Emission",subtitle:null,isOpenForSubmission:!1,hash:"e1bd25a76712d1cb8792820acf2ff001",slug:"coherence-and-ultrashort-pulse-laser-emission",bookSignature:"F. J. Duarte",coverURL:"https://cdn.intechopen.com/books/images_new/10.jpg",editedByType:"Edited by",editors:[{id:"13752",title:"Dr.",name:"F. J.",surname:"Duarte",slug:"f.-j.-duarte",fullName:"F. J. Duarte"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11",title:"Multi-Robot Systems",subtitle:"Trends and Development",isOpenForSubmission:!1,hash:null,slug:"multi-robot-systems-trends-and-development",bookSignature:"Toshiyuki Yasuda",coverURL:"https://cdn.intechopen.com/books/images_new/11.jpg",editedByType:"Edited by",editors:[{id:"5669",title:"Dr.",name:"Toshiyuki",surname:"Yasuda",slug:"toshiyuki-yasuda",fullName:"Toshiyuki Yasuda"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12",title:"Numerical Simulations",subtitle:"Examples and Applications in Computational Fluid Dynamics",isOpenForSubmission:!1,hash:null,slug:"numerical-simulations-examples-and-applications-in-computational-fluid-dynamics",bookSignature:"Lutz Angermann",coverURL:"https://cdn.intechopen.com/books/images_new/12.jpg",editedByType:"Edited by",editors:[{id:"13342",title:"Prof.",name:"Lutz",surname:"Angermann",slug:"lutz-angermann",fullName:"Lutz Angermann"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"13",title:"Paths to Sustainable Energy",subtitle:null,isOpenForSubmission:!1,hash:null,slug:"paths-to-sustainable-energy",bookSignature:"Jatin Nathwani and Artie Ng",coverURL:"https://cdn.intechopen.com/books/images_new/13.jpg",editedByType:"Edited by",editors:[{id:"13730",title:"Dr.",name:"Artie",surname:"Ng",slug:"artie-ng",fullName:"Artie Ng"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"14",title:"Traveling Salesman Problem",subtitle:"Theory and Applications",isOpenForSubmission:!1,hash:null,slug:"traveling-salesman-problem-theory-and-applications",bookSignature:"Donald Davendra",coverURL:"https://cdn.intechopen.com/books/images_new/14.jpg",editedByType:"Edited by",editors:[{id:"2961",title:"Prof.",name:"Donald",surname:"Davendra",slug:"donald-davendra",fullName:"Donald Davendra"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],publishedBooksByAuthor:[]},onlineFirst:{chapter:{type:"chapter",id:"72293",title:"The Impact of Payer and Reimbursement Authorities Evidence Requirements on Healthcare Solution Design for Muscular Dystrophies",doi:"10.5772/intechopen.92553",slug:"the-impact-of-payer-and-reimbursement-authorities-evidence-requirements-on-healthcare-solution-desig",body:'
Only around 5% of the 7000 identified rare diseases have an effective treatment and this is echoed in neuromuscular conditions [1]. Recent years have witnessed a number of cancelled developments of therapeutic interventions for muscular dystrophies that were at advanced stages of development, while other interventions have been denied market authorisation, both in the US and Europe due to a lack of clinical efficacy. This means it is even more important to convince payers of the value for money of the few treatments that make it to market.
Obtaining market authorisation does not guarantee that payers will reimburse the product, that is pay for it, as growing concerns regarding the growing gap between the demand for health services and technologies and the available resources have increasingly introduced systems to assess the value for money of those products coming to market. The predominant processes for these value assessments are called health technology assessments (HTAs). Since the introduction of the National Institute for Health and Care Excellence (NICE) in 1999 in England, HTAs have spread throughout the world and now nearly every country has HTA organisations in place to help payers determine the value for money of new healthcare technologies.
These value assessments conducted by these HTA organisations consist of compiling, analysing, assessing and appraising the evidence available to show whether the health and economic benefits of a product compared to the standard of care (in the jurisdiction in question) are sufficient to justify the price, above and beyond the requirements of regulatory authorities.
There remains a lack of understanding and implementation of these considerations in clinical development without which companies will struggle to gain reimbursement.
Negative reimbursement decisions by payers hinder access to the drug substantially, if not completely. Delays in reimbursement decision-making can lead to substantial delays in a new product gaining market access. Both delays and negative decisions impact adversely on sales and consequently return of investment (ROI). Furthermore, where the evidence presented to reimbursement decision-makers bears too much uncertainty it is highly likely that the accepted price will be far below the one required by the manufacturer. Thus, investing in better data collection can support reimbursement at an acceptable price.
Given the central role played by clinical trials in generating the evidence required for HTAs, everyone involved in designing clinical trial programmes and evidence generation needs to be aware of the methods and procedures required to generate the evidence required for HTAs above and beyond the evidence requirements for regulatory approval.
This is critical for developing solutions for rare diseases, such as the muscular dystrophies, due, fundamentally, to the low number of patients, and the significant variation of disease progression and severity among the patients that makes the generation of authority stipulated convincing statistical evidence significantly more complicated [2]. There are still many treatments in late stages of clinical validation (phase II and III) and more in earlier stages of development [3] targeting as many different aspects of this multi-faceted disease as possible.
In this chapter, we present a framework for what to consider during the design of clinical trials and evidence generation alongside and beyond clinical trials for muscular dystrophies to address the evidence requirements to gain reimbursement by payers.
Concerns regarding the growing gap between demand for health services and technologies and available resources have long created the need to regulate healthcare expenditure and governments have increasingly introduced formal systems to assess the value or money of healthcare technologies coming to market [4]. Nearly every country has formal reimbursement authorities in place to help payers determine whether a health technology is worth paying for. Value assessments conducted by these authorities consist of compiling and analysing the evidence to show the health and economic benefits of a product compared to the standard of care are sufficient to justify the price desired beyond the requirements of the regulatory authorities [4].
Delays in reimbursement decision-making can lead to substantial delays in a new product gaining market access and negative reimbursement decisions by payers hinder market access substantially and thus impact adversely on sales and return on investment. Furthermore, where the evidence presented to reimbursement decision-makers bears too much uncertainty it is highly likely that the accepted price will be far below the one desired by the company. Thus, investing in better data can support reimbursement at a desired price.
Given the central role played by clinical trials in generating evidence for use in reimbursement assessments, those involved in designing clinical trials need to be aware of the evidence requirements of payers and reimbursement authorities. These differ and go beyond those of regulatory authorities.
We also explore the specifics of these issues and suggest actions that can be taken from conceptual design throughout the development of interventions that can help manufacturers unlock market access for their products. While all of the above applies to all pharmaceuticals, it is even more important in the context of muscular dystrophies and other rare disorders where data can only be generated in a small number of people as compared to more common conditions such as type 2 diabetes.
From either a patient care and management procedure or a healthcare solution development perspective, in an ideal scenario three components are needed:
An established and clearly defined pathophysiological assessment of the development of the disease that enables an accurate prognosis at any time point in the disease progression that a standardised diagnosis confirms;
An overlapping and reimbursement agency-approved care pathway that defines what needs to be done at every point throughout the disease; and
A list of the standards of care that are purchased and used throughout the care pathway.
These three components can be further complemented by population health dynamics that also integrates environmental and socio-economic components linked to patient groups that further refine best approaches.
For highly prevalent diseases, the large number of patients that are affected generates a large source of data from which statistically relevant conclusions can be drawn that inform the points above enabling healthcare practitioners to make optimised patient care decisions, while innovators can look at the pathway to identify ‘pain points’ for which a specific product can be created to generate a solution. For conditions such as many forms of cancer or cardiovascular diseases, this has been further augmented as global patient data collections have become integrated, thereby generating even more specific and highly tailored approaches.
Rare diseases do not and have never had the same broad evidence base as the highly prevalent diseases and that has been recognised by the key stakeholders including regulatory authorities and governments who have introduced incentives to encourage the development of new treatments for rare diseases. These stakeholders have globally networked and generated information and data resources such as the global academic network Treat NMD group (https://treat-nmd.org) focusing on all neuromuscular diseases to create a critical mass, ecosystem and hub of expertise.
Duchenne muscular dystrophy is a serious genetic disease which is life-threatening and shortens the patient’s life substantially. DMD is an X-linked disorder caused by mutations in the dystrophin gene and it is the most frequent muscular dystrophy in boys affecting 1 in 3500 live births [5, 6] and 1 in 50 million girls [7]. DMD is usually diagnosed before the age of 6. The disease causes progressive and unyielding muscle weakness frequently identified in the early toddler years when the child begins to miss development motor milestones [8, 9]. Loss of ambulation occurs generally around the age of 12. Only a few DMD patients survive beyond the third decade; most die because of respiratory complications or heart failure due to cardiomyopathy [10, 11, 12, 13].
From a clinical care perspective in DMD, because clinical care recommendations did not previously exist, the US Center for Disease control (CDC) established the DMD Care Considerations Working Group, who in 2010 published the first comprehensive DMD care considerations [12]. These were revisited and updated in 2018 to provide a complete care programme that addressed 11 key topics that occur in DMD, divided into five stages of disease [13, 14, 15]. The five recognised stages are diagnosis, early ambulatory, late ambulatory, early non-ambulatory and late non-ambulatory, and the 11 key topics include neuromuscular, rehabilitative, endocrine, gastrointestinal/nutritional, respiratory, cardiac, bone health, orthopaedic, psychosocial and transitions management. Within these publications the precise list of tests and actions that should be performed for these 11 topics at each stage are indicated. These initiatives have generated enormous amounts of benefit as proven by increased lifespans of patients and, critically, a drive to obtain even more detail about all the different characteristics of the disease and its precise progression [12, 16, 17, 18, 19]. This has included a push to reintroduce newborn screening tools and a larger effort to understand the pathology at the earliest times of the disease, which has recently been approved by the FDA [20].
The widely held and logical argument is that the sooner the intervention is started, typically in the young child, the greater the possibility that quality of life, morbidity and length of life can be enhanced.
As the prelude to this chapter, we have analysed the approved patient care and management pathways and integrated more recent published reports on early stage assessments and longitudinal monitoring, incorporated in as much insight as possible from the most current knowledge to create a best ‘what we know’ about the progression of muscular dystrophies, with a bias towards Duchenne muscular dystrophy (DMD). This has been done on the basis that by analysing one muscular disease as comprehensively as possible it will complement insights from our peers for the additional muscular dystrophies.
All muscular dystrophies are genetic; DMD is X-linked and can be an inherited mutation, a spontaneous mutation or due to germline mosaicism. The onset of DMD is illustrated by a list of manifestations that serve as ‘possible indicators’ of the disease that then precipitates a diagnostic assessment pathway that confirms or refutes the evaluation [13].
As demonstrated in the Norwegian paediatric DMD population, if there is a family history of muscular dystrophy, then this can mean that a confirmed diagnosis is possible almost immediately (mean age at diagnosis 2.8 years with a standard deviation of 3.2 years) [21] if there is not; then indicators such as speech delay, high Creatinine Kinase or transaminases, abnormal gait or delayed motor development followed by more specific genetic tests are used to confirm diagnosis that may not occur until the child is between 3 and 6 years of age. Newborn screening for high CK is a good predictor of DMD.
Why is this important? Until recently, understanding of muscular dystrophy during the neonate phase was very limited and it was speculated that there was a ‘honeymoon period’ during which the disease did not develop significantly. Following the creation of the Bayley III child development assessment tool, the MDA-DMD clinical research assessed 24 children with ages ranging from 0.37 months to 2.99 years [9]. The Bayley III tool assesses children in five developmental domains: cognition, language, social–emotional, motor and adaptive behaviour. It exists in tailored forms for specific diseases. For all patients, their language and cognitive skills were lower than healthy patients, as were their fine motor skills, while the gross motor skills were more significantly impacted, implying that the large muscle groups and the core muscle groups are being affected in these patients at an early age, and it was observed that these skills declined with age. In a 1-year follow-up, declining motor function continued to be observed [22]. This work was further confirmed in a larger study involving 114 patients in which delays in gross motor development were observed [23]. Similarly in the 4D-DMD study performed comparing the healthcare records and questionnaires of 76 patients with DMD compared to 19,000 patients from the general population revealed impaired gross motor development, with first signs visible at 2–3 months of age and more evident by 24 months of age [24].
Additionally there is early fibrosis in the newborn, and the possibility there may be a cardiac involvement without overt clinical signs [25], whether there are endocrinological or respiratory issues early in development is still unclear [26]. Given the gross motor involvement, it is possible that the diaphragm maybe affected, but no respiratory analyses in very young children have been reported. The diaphragm and abdominal muscles work in tandem to stabilise the spine and trunk and enable voluntary limb movement [27].
The standard of care is to start steroid treatment and physiotherapy from the age of 3 or 4, cardiac monitoring and spirometry, measuring pulmonary function and vital capacity, from the age of 6 [13, 14, 15] and it is known that from the age of 6 onwards there is respiratory decline peaking at around 14 years of age, with a forced vital capacity (FVC) of 1 L [28] while a healthy child typically has a FVC of over 3 L. Those patients with a strong FVC have been reported to live longer [29], so we can speculate based on the outcomes from the Bayley III analysis if respiratory assessment or diaphragm thickness analysis may also be worthwhile measures at early stages of disease that can be assessed more frequently in the family practice setting, providing the equipment is available and correctly maintained [30].
How to approach this from a rehabilitative approach, especially in the neonate, given their developmental and overall regenerative capacity could be avenues to explore experimentally in animal models. It is recommended that excessive and high-impact exercise should be avoided in these patients due to the induction of muscle damage, without the normal muscle repair mechanism, thereby augmenting inflammation and fibrosis [31]. However if there is specific muscle involvement enabling a localised application of regenerative approaches combined with occupational therapy or low-intensity rehabilitation, this may provide a foundation to prevent core muscle decline, and enable other therapies to be sequentially applied. Experimentally, this has been demonstrated in traumatic muscle damage [32, 33], while in Sarcopenia low-intensity electrical stimulation has demonstrated benefits [34, 35]. Whether these approaches can be innovated and combined, while addressing the genetic aspect is an open question; however, as shown for traumatic spinal cord injuries, combination approaches can offer benefit [36].
What happens next, generally to the patient is well documented and increasingly being reported linked to the type of mutation that the patient has (nonsense, frameshift, splicing site, pseudoexon or missense). Using North Star Ambulatory Assessment (NSAA) as the outcome assessment, mild increases are observed in functionality very early and then from the age of 3 to 6.5 years the patient’s ambulatory capacity increases [16] but it never reaches the age standardised healthy norm. Physical support maybe needed from the age of 8, and between the ages of 10 and 12 most patients no longer have the ability to walk, which also leads to orthopaedic-related issues (contractures in the ankles and scoliosis in 90% of patients) with associated impacts on cardiovascular and pulmonary function.
It is important to look at the specifics of each patient because of the patient variability (genetic type and likely population health-related compounding factors) and the 11 topics that are considered essential in patient care and management, as demonstrated by the studies of Phillips and Brogna [29, 37]. Despite mean assessments based upon Spirometry or 6MWT that indicate downward decline, at the individual patient level while eventually each patient’s condition deteriorates, the variation between the genetic mutation (whether it is an early or late deletion, a duplication or premature stop codon) related to functionality or lung capacity indicates that there are additional compounding factors that influence pathology progression.
One trend does seem to be clear and that is when a patient’s condition does deteriorate, it happens rapidly, in less than 12 months. This would suggest that a higher frequency of testing may be needed, which would for most families present a logistical problem. Therefore, patient management solutions that can be implemented either virtually as that performed in standard cardiac monitoring or in family care practices may offer innovative interim patient care and management alternatives.
Considering that every patient is typically monitored via a dedicated specialist centre, who without question perform as many of the recommended tests as possible, because no correlation has been reported between disease progression at the biometrics being assessed, there may be external factors influencing disease progression. This is not a strange phenomenon, in the instance of asthma, increased incidences of asthma are reported in lower income families, because in many cases the houses can be either mouldy or damp resulting in spores entering the child’s lungs and inducing the disease [38]. It may therefore be worthwhile to integrate Population Health specialists into the ecosystem to provide additional insights, which may not generate an intervention, but will define an optimised and implementable care pathway that integrates for as many patient-specific non-disease specific variables as possible that can include broad social, socio-economic, environmental conditions as well as healthcare policies.
The cumulative outcome will hopefully be not only a globally standardised care pathway for all patients with muscular dystrophy, but also the creation of intervention and diagnostic innovations that will address reimbursement agencies’ requirements and standards.
Concerns regarding the growing gap between demand for health services and technologies and available resources have long created the need to regulate healthcare expenditure and governments have increasingly introduced formal systems to assess the value for money of healthcare technologies coming to market [4]. The predominant processes to do so are health technology assessments (HTAs) (ref).
The introduction of the National Institute for Health and Care Excellence (NICE) in 1999 in England significantly contributed to the globalisation of HTAs [39]. Nearly every country now has an HTA organisation in place to help payers determine the value of new medical interventions (Figure 1) [40].
Countries with formal HTA systems worldwide.
Historically, HTAs were performed after regulatory marketing authorisation had been granted. Due to the resulting gap between marketing authorisation and reimbursement, HTAs tend now to start much earlier—often in parallel with regulatory approval processes.
While there are differences between countries regarding defining the value of a new health technology, certain central requirements are common and can be addressed in clinical trials and evidence generation alongside and beyond clinical trials.
HTA is constantly evolving—the methods and processes as well the countries using it. Therefore, manufacturers developing healthcare technologies need to follow and engage with HTA developments either directly or through the use of expert consultants.
Regulatory authorities around the world require manufacturers to demonstrate the risks vs. benefits and quality based on clinical and non-clinical information. Reimbursement authorities require companies to demonstrate the comparative value of their product vs. the standard of care used in their jurisdiction. To do this, they appraise a new health technology or indication in comparing a set of product attributes relating to its efficacy, safety, impact on quality of life (QoL) and functional status and pricing compared to the current standard of care.
Evidence used in HTAs for assessing the relative clinical and cost-effectiveness of new pharmaceuticals comes from a variety of sources, such as systematic literature reviews, indirect treatment comparisons and economic modelling. However, clinical trials conducted during the drug development process provide the most important source of treatment effect data for HTAs.
In recent years, some regulators including the EMA and FDA have taken steps to enable faster access to some drugs for rare conditions. For example, grant conditional authorisation to treatments such as Ataluren for DMD. This is not without controversy and HTA authorities have expressed concern that there may be insufficient evidence available for them to determine the effectiveness and value of such treatments.
Traditionally, most medicines received marketing authorisation after completion of large phase III clinical trials. Increasingly, medicines, especially such with novel or breakthrough status, are receiving regulatory approval based on much smaller phase II trials and/or non-comparative ‘single arm’ trials.
Therefore, it is important to consider the specific evidence requirements for HTAs (i.e. core of relative clinical and cost-effectiveness evidence) much earlier in clinical development programmes, that is, when designing phase II trials as well as when designing phase III trials.
Pharmaceutical companies need to consider five critical areas when designing clinical trials to be HTA ready as well as ready for regulatory authorities:
Choice of comparator
Measurement of clinical effectiveness
Quality of life (QoL) and patient reported outcomes
The collection of resource use data
Follow-up time of the trial
Non-comparative/single arm trials create issues when HTA decision-makers try to compare the new technology vs. the standard of care. Placebo-controlled trials result in similar issues, if the placebo arm of the trial differs substantially from clinical practice. Both result in the need of extensive indirect treatment comparisons (ITCs), thus weakening the relevance and robustness of the clinical evidence in HTAs.
We recommend, wherever possible, to use the standard of care as the comparator. This may be difficult where there is no gold standard and/or where clinical practice across and/or within countries involved in the trial varies. In such cases, we recommend consideration of the use of an active comparator based on physician choice to enable treatment comparisons relevant to HTA decision-makers in their respective jurisdictions.
HTA requires outcomes to be patient relevant, and there is a growing interest in the use of patient reported outcome measures (PROMs) in clinical trials [41, 42, 43]. In some disease areas, for example cancer, it may not be possible to power a trial to capture the treatment effect on hard outcomes, such as mortality/overall survival, and surrogate endpoints are used, such as progression free survival, which is an issue for ensuring the trial results are relevant to patient outcomes. However, surrogate endpoints can be useful when a clear and robust link can be established with patient relevant outcomes. For example, as for the link between HbA1c in type 2 diabetes and cardiovascular events. However, this is only when those links have been or can be validated by studies, so that HTA decision-makers can accept them.
We recommend, where possible, to select endpoints relevant to patient outcomes (for example survival, PROMs—see more below). Where this is not possible, we recommend establishing robust links between surrogate endpoints and patient outcomes and to validate them in separate studies or with external databases.
When considering the selection of endpoints for a clinical trial, it is also important to keep in mind how the data will be used in HTAs where the new technology will be compared with other technologies used in clinical practice via an ITC. Therefore, it is important to review which endpoints have been collected in trials of most relevant comparator technologies to enable such treatment comparisons.
We recommend reviewing the endpoints used in previous trials, undertaking validation of these measures, whether the MCID is relevant and a predictor of patient outcomes and making a recommendation for consistent measures going forward to support comparisons between treatments.
However, there is non-alignment between the entities that provide market authorisation and those that perform HTAs. The FDA strongly recommends placebo-controlled trials [44], whereas the EMA suggests placebo in a two-way design study that enables a standard of care add on. With the caveat that if patients are being treated with corticosteroids, further patient stratification between the groups should be performed [45]. In both cases, a restoration of function or slowing decline is considered the main recommended endpoint, along with additional studies addressing activity levels, cardiac function and respiratory activity, while patient reported outcomes are suggested but not recommended.
Similarly, NICE in their evaluation of Idebenone, indicated that outcome measures to be considered could include pulmonary function, cardiac function, walking ability, motor function, muscle strength and HR-QOL, to assess the impact on quality of life [46].
This, however, is not reflected in the analysis of phase II and III clinical trials either performed or ongoing for muscular dystrophies. Of the 19 drugs tested in numerous phase III studies only 6 included PRO to enable a HR-QOL assessment, while of the 18 in phase II studies only 2 included PRO. One has to anticipate that because of the low number of patients in rare disease clinical trials and the importance of the impact of obtaining quality of life information to enable patients to have access to these medicines, PRO should become a standard in clinical studies, and that the PRO should be standardised throughout the field.
HTA organisations use QoL and functional status data either for use in cost-effectiveness evaluations or as individual value attributes of additional benefit a new technology offers. A separate economic model needs to be developed (typically in Excel) to utilise input data from the clinical studies and other sources.
To support the economic value case for a new pharmaceutical, the instruments used in the trial need to allow the generation of utilities (QALYs). For utility measurement, data from generic health status measures, like the EQ-5D, tend to be preferred by HTA organisations.
For muscular dystrophies, PROs that inform changes in quality of life have been investigated to identify and tailor QoL since at least 2011 [47, 48]. The issue is that the consequences of the disease are broad and diverse, vary from patient to patient and change as a function of age. For the most juvenile patients, outcomes are dependent on parent and physician reports due to a vocabulary limitation common to all young children. To some extent, this can be replaced with the overlapping Bayley III assessment, which can assess neonate responsiveness and functionality while simultaneously evaluating if the child has developmental differences [9]. Bayley III is not a QoL indicator per se, but in the context of neonate development, the comparison between healthy and DMD patients has revealed outcomes that would suggest that this could be used for the earliest possible assessment. It is essential to read this publication for the indicated outcomes for functional expectation of healthy neonates and how this compares to patients with muscular dystrophy, because of the emphasis that regulatory bodies give to functional gains.
Following this, PROs are obtained routinely using the Paediatric Outcomes Data Collection Instrument (PODCI), SF-36 Health survey [41] and Neuromuscular module and Generic Core Scales of the PedsQL, which are also suggested by the EMA [45]. However, measuring QoL becomes significantly more complex as the patient grows. It has been reported that QoL outcomes using the PedsQL become unreliable as the patient ages [47], at least in the context of restoration of function, as defined by regulatory bodies versus increases in quality of life. The insinuation is that a restoration in function does not necessarily correlate to an increase in quality of life, which reinforces the concept that selected population health-related or additional pathophysiological measurements may need to be integrated into the appraisal as a third axis.
Additional research has been performed utilising the WHO ICF-CY [19, 49, 50], while the most comprehensive research on identifying, designing and optimising PRO specific for the muscular dystrophies has been reported from ScHARR [41, 42, 43] that forms a core part of the Project HERCULES initiative, a project led by the patient organisation Duchenne UK, aimed towards creating a suite of disease level HTA evidence including QoL assessment for DMD. The emphasis is that the QoL questionnaire needs to retain core expectations while also expanding the readouts as a function of neurological gain as the patient matures and can expand their expressiveness.
In muscular dystrophies, Project HERCULES (see below) is developing an optimised Duchenne muscular dystrophy (DMD)-specific instrument to create a preference-based measure to meet the needs of HTA.
Besides their use in cost-effectiveness evaluations, the use of generic and condition-specific instruments will generate data to inform HTA decision-makers’ assessments of the additional benefit of the new technology compared to the standard of care as individual value attributes.
QoL and functional status data should be collected at baseline and throughout the trial and follow-up period.
We recommend collecting QoL and functional status data using generic health status measures that allow the generation of utilities, as well as including a condition-specific instrument. In selecting which PROMs to choose, it is important to review the trials of the most relevant comparators to enable better comparison between technologies during HTAs.
This includes hospitalisations, outpatient/GP appointments and tests/investigations to inform the cost-effectiveness analysis. There is no universally recognised method for economic data collection in clinical trials and a variety of techniques are used. The methods and instruments used should reflect the health condition to new technology addresses. The researcher planning the trial should again review the trials of the most relevant comparators to identify potential methods and instruments.
Resource use data should be collected at baseline and throughout the trial and follow-up period. However, resource use data collection from a multinational clinical trial should be performed with caution due to the concerns over the generalisability of the data for country-specific HTA submissions. Hence, there is a key role for local validation of resource use estimates from a trial and/or observational data collection. Additional Burden of Illness studies should be undertaken alongside trials to show real-world evidence.
Studies should have an appropriately long enough follow-up time to enable the collection of consistent, sufficient and robust data relevant to HTA decision-makers. Minimising uncertainty about clinical effectiveness may be a particular challenge for life-long progressive conditions with limited data such as muscular dystrophies and there is no fixed time period favoured by HTA bodies.
In addition, a plan detailing how and when individual endpoints will be collected is essential. This should include the frequency, methods, sources and time horizon within the data. Besides the data collection plan, the researcher planning the trial should also consider the development of a specific health economics/HTA statistical analyses plan (SAP) covering such aspects as to how PROM and resource use data will be analysed for HTA and use in economic models. This would complement the regular clinical study SAP.
Some HTA bodies, for example NICE, offer HTA-specific scientific advice to developers of health technologies to help them develop evidence required for HTAs [51]. Also, the EMA and EUNetHTA (EU body responsible for co-ordinating HTA methods and policies in Europe) offer a joint scientific advice programme to companies with HTA organisations involved.
All of those processes come with varying requirements for preparation and company input and varying levels of opportunities for engagement with the involved parties.
Advisory board meetings with health economists with clinical trial experience for selected key territories, HTA experts and clinicians to review and input into clinical trials.
One-to-one meetings with payer/HTA experts to review and gain input for clinical trial programmes from specific experts for specific regions and/or countries.
Working with specialist health economics consultants with clinical trial, HTA scientific advice and HTA experience to review plans, gain input into clinical trials, to develop whole HTA scientific advice programme tailored to the individual company requirements and to provide wider market access and HTA advice also supporting and/or conducting individual projects.
Patient and family input is crucial to fully understand the impact of the disease, on health, quality of life, socially and financially as well as any practical considerations relating to the feasibility of the trial design.
For all of the above, we recommend working with health economists with clinical trial and HTA experience to review plans, gain input into clinical trials, to develop whole HTA scientific advice programme tailored to the individual company requirements and to provide wider market access and HTA advice also supporting and/or conducting individual projects. This can also include the consultants helping the company to navigate the official procedures.
Beyond clinical evidence generation, developers of healthcare technologies need to develop a set of HTA value propositions covering the impact their technology will have on the unmet need, its comparative effectiveness demonstration (planned and expected and/or based on potentially available data), patient reported outcomes (including quality of life), cost-effectiveness, and resource use, costs and budget impact as well as covering a PICO (Patient, Intervention, Comparator and Outcomes) statement.
Companies need to conduct early HTA-specific gap analyses and HTA feasibility assessments to identify gaps in their own as well as their comparator’s evidence base to allow for sufficient time to fill those through evidence generation within, alongside and beyond clinical trials. With this, it is also important to remember that HTA preparations need to start early with HTA input into phase II clinical trial planning and designing at the very latest and from there on being a constant and equal (to regulatory) part of any development as getting reimbursement is equally important as getting a marketing authorisation.
Companies need to conduct early economic modelling and payer research to inform their pricing strategy reflecting their evidence base. Technologies that are too expensive and do not have a significant benefit over existing alternatives are unlikely to be approved. The key driver of cost in many economic evaluations submitted to HTA organisations is the price of the technology. Where the list price is too high for the technology to be approved for reimbursement, companies can provide discounts and/or other commercial arrangements to reduce the cost to an approvable level. There are also instances when a new technology may be additive to existing standards of care. Where this care is already expensive, it is possible for a new treatment to not be cost-effective even at zero cost [52].
In other instances, it is not the list price of the technology but the uncertainty of the submitted benefits driving the need for a discount and/or commercial arrangement. In HTAs evidence uncertainty is critical and higher the uncertainty the lower the acceptable price will be. Therefore, investing in better data and filling evidence gaps as early as possible can support a better price and avoid the need for a discount and/or commercial requirement.
Economic modelling can help a company to identify the potential need for a discount or commercial arrangement and where they are required the potential magnitude required.
Beyond evidence generation and pricing, manufacturers should follow and engage with HTA developments, follow comparator HTAs to inform their own HTA preparations and be open, transparent, collaborative and realistic when engaging with HTA authorities.
Support is available to companies throughout the whole process from early development through to the conclusion of individual HTAs from official bodies, like HTA organisations, as well as from experienced HTA expert consultants. Companies should make use of the support available to them.
Furthermore, stakeholders from different backgrounds involved in addressing challenges in healthcare are increasingly working together cross functionally and globally. Developers of treatments for muscular dystrophies should also consider such approaches where they are not already happening. One outstanding example of such a collaboration in muscular dystrophies is Project HERCULES [53, 54].
In the field of Duchenne muscular dystrophy (DMD), one of the most common and severe forms of muscular dystrophy, Duchenne UK set up Project HERCULES (HEalth Research Collaboration United in Leading Evidence Synthesis) to develop tools and evidence to support HTA for new treatments for DMD [53, 54, 55].
Many pharmaceutical companies are developing potential treatments for DMD and are working individually to develop their approach to HTA. The variety of methods in use and the difficulties of generating data can lead to delays in introducing new treatments and inconsistent decision-making.
Duchenne UK invited pharmaceutical companies with a DMD product in development to a training day in February 2017 to explore modelling and HTA in DMD. This led to the establishment of Project HERCULES, a collaborative global project bringing together patient organisations, clinicians, academics, nine active pharmaceutical companies, HTA agencies and other advisors.
Project HERCULES has generated a set of disease-level evidence and tools including a natural history model, burden of disease data, a de novo DMD-specific quality of life metric, and a core economic model. These individual workstreams have been developed in parallel through an iterative process enabling evidence generated for one work stream to inform the others. This iterative approach ensured that input from clinicians, patients and carers and other experts was used for multiple purposes minimising the demands on stakeholders.
The leadership of a patient organisation enabled access to data sources and expertise that may be inaccessible for individual or industry researchers. The patient organisation was also able to recruit patients and parents to participate in the research through the use of social media and offline networks. There have been clear efficiencies for manufacturers in being able to access evidence and expertise and a greatly reduced cost compared to developing these evidence and tools in isolation.
The collaborative approach taken by Project HERCULES was not without challenges. Researchers often needed to learn to explain complex concepts in accessible language to ensure patients and lay members could effectively contribute. Balancing the input from patients and families with clinical, industry and HTA experts has also been challenging. Project HERCULES selected researchers in part by their readiness to work collaboratively with stakeholders ensuring that they were working closely with the other research teams and actively listening and responding to all the information obtained, and not simply seeking confirmation for what they expected to find.
Despite the challenges, Project HERCULES has consistently taken a collaborative approach that has had a clear impact on each workstream:
Enabling researchers to test assumptions against lived experience and develop their own understanding of the condition and care pathway
Identification of meaningful disease stages including the previously overlooked transfer state between the traditional stages of late ambulatory and early non-ambulatory. Patient and parents told researchers about the importance of being able to weight bear for a period following the loss of ambulation. This state has been incorporated into the natural history model, which informs the other work streams.
Development of a bespoke Quality of Life preference based measure that better reflects the lived experiences of those with DMD as well as the views of clinicians and other experts.
An economic model that builds on the actual experience of clinicians, patients and families
A burden of illness study focusing on what is most important to clinicians, patients and families.
In healthcare, and particularly therapeutic intervention, development takes a long time, typically over 14 years [56, 57], and is costly (up to $2.6 billion, [58]), which means that significant risk has to be carried for a long duration before knowing if the product was worth the investment. However, in the context of rare diseases, the scenario is significantly different. Whereas the development up to launch of a medicine for a very common condition may cost $2.6 Billion, for the muscular dystrophies the value might be closer to $400 Million. The number of patients involved in the trials are significantly lower, the duration of the trials shorter and upon market release, an extensive sales force is not necessary, as patients are typically referred to centres of excellence [59, 60, 61], and clinicians who focus on treating patients with rare diseases are typically well versed in developments in the field, while patients associations perform stellar work in communicating with patients and their supporters what is happening [7, 62, 63, 64, 65, 66, 67, 68]. As explained above, achieving a marketing authorisation does not guarantee reimbursement that companies need to achieve before they can realise uptake and sales.
This leads us to two questions: (a) what impact integrating HTA requirements in clinical trial design has on investment decision-making, and (b) what impact it has on return on investment.
To answer the first question, we need to look at how pharmaceutical investment decisions are informed.
The decision to invest in the creation of a medical product, as for all other businesses, hinges on the definition of the market size, the terminal market value. The terminal market value is then reverse calculated to the potential present value by integrating in phase specific costs, risks and probabilities of success to give a net present value (NPV). If the NPV is positive, then the innovation is considered worthwhile to invest in, whereas if it is negative, the rule of thumb is to not invest.
NPV calculations are only as good as the data used to generate them, and both accurate and comprehensive values ideally should be used, based on real market dynamic, the latest clinical success rates and considering the latest reimbursement approaches (such as HTAs). Thus, designing clinical trials that are more likely to result in better data and addressing HTA evidence requirements improve NPV calculations and thus optimise investment decision-making [69]. However, it is important to state that there is the possibility that market authorisation agencies and reimbursement bodies may not accept clinical data from other jurisdictions due to different standards and regulations. Therefore, while NPV outputs are additive, the developer may need to assess if different clinical trials need to be performed in different locations and if and how the data can be used within a comprehensive evidence dossier that can be submitted to as many different agencies as possible.
The answer to the second question is that investing in better evidence generation will lead to higher chances of gaining desired reimbursement at the desired price, thus unlocking market access and sales potential early, thus having a positive impact on ROI. For the rare diseases, accounting for post-marketing surveillance, manufacturing and general admin costs, to reach a balance of zero, the product will need to generate at least $1 Billion in life time sales; to enable the innovators to sustain and expand their pipeline, generating additional new interventions for other rare diseases, life time sales between $2 Billion and $8 Billion would be required. Based on marketing authorisation restrictions on recently approved DMD interventions, that are based upon the differing forms of dystrophinopathies, this revenue level would need to be generated from generating a beneficial effect (clinical effectiveness and cost effectiveness) for 10% of the muscular dystrophy population, who would likely need to administer the solution every year for the rest of their life, that could be an additional 25 years based on the increased standards of care. This combined information is then used to define the agreed price of the solution with the reimbursement agency, within the specifics of the healthcare system and marketplace in each different geography (this can be an entire country or a region within a country).
Governments have tried to be flexible to account for the market risks, policy changes have been implemented, such as the orphan drug definition in the EU. Because of the potentially low revenue potential, investing in solutions for rare diseases carries a higher risk, as costs cannot be recovered, therefore acts that provide market exclusivity for 12 years for paediatric diseases, in competition with ‘similar competitive products’. Additionally, to facilitate R&D in healthcare, most countries offer R&D tax credits, independent of the source of the R&D funding, and using a very broad definition of what constitutes a R&D cost to stimulate such endeavours. These credits can be used to offset taxes on profit, providing the entity reinvests the revenue.
Conceptually for a paediatric rare disease, the rule may need to be revisited to reconsider what is the definition of a similar product to provide clarity to innovators. Arguably it is any intervention that offers disease correction, which can be a very broad definition or is it based upon similar mechanisms of action; ideally innovators would need this point clarified to enable better clinical trial design. This is reflected in the clinical trials that are ongoing and appear to be following the conceptual design associated with major diseases, that is an ‘all or nothing’ response based upon the intervention being assessed.
Given that the disease takes years to manifest itself, and varies significantly from patient to patient as seen in other progressive degenerative diseases or traumatic injuries with inconsistent and differing measurements, it is more likely that a spectrum of concepts and solutions need to be integrated together as function of the patient and the tissue damage at that specific stage within the complete disease progression to provide beneficial outcomes; this is likely going to include standard chemical entity interventions, anti-inflammatories and physiotherapy and potentially stem cells, biomaterials, genetic correction, tailored and designed as a comprehensive intervention solution tailored to the patient and their population health status.
In summary, we would like to emphasise that for a product to be able to get a positive HTA recommendation leading to reimbursement by payers, manufacturers need to carefully consider the evidence needs of HTA authorities when planning clinical trials and evidence generation programmes.
For each new product, this should start early, that is when planning phase II trials, and continue throughout the clinical development process in order to optimise the chances of gaining reimbursement and consequently return of investment.
Beyond evidence generation and pricing companies follow and engage with HTA developments, follow comparator HTAs to inform their own HTA preparations and be open, transparent, collaborative and realistic when engaging with HTA authorities.
Support is available to manufacturers throughout the whole process from early development through to the conclusion of individual HTAs from official bodies, like HTA organisations, as well as from experienced HTA expert consultants. Additionally, innovative initiatives, such as Project HERCULES, are existing to support developers but also serve as examples of what is possible and can be done beyond existing support structures and options. Manufacturers should make use of the support available to them.
Furthermore, addressing the evidence requirements of payers and HTA organisations in clinical trials and other evidence generation can lead to improved investment decision-making and have a positive impact on ROI.
It is also important to emphasise that developers of healthcare technologies need to address the evidence needs of reimbursement decision-makers early and throughout the development process in order to optimise their chances of gaining market access at a desired price unlocking ROI. To obtain and support this outcome, there may need to be a reconfiguration of the muscular dystrophy R&D ecosystem. A large amount of fundamental research has been and is still performed in the muscular dystrophies, mostly paid by charities such as MDA, Telethon, Duchenne and AFM, to name only a few. In no way does the volume of research and funding for muscular dystrophy compare to the major diseases.
For the major diseases, the years of highly funded fundamental research has resulted in outcomes that have translated to the clinic for the benefit of patients that is founded upon a significant amount of independently validated and reproduced data. Naturally, at the public funding level, policy is therefore biased towards encouraging fundamental research to have a translatable dimension to justify to the taxpayer the expense.
Rare disease researchers have not had a large knowledge resource but find themselves in the position that they need to accelerate their translatable research, due to patient need, without the same foundation of knowledge to rely upon. This is not going to change; however, different approaches to managing the knowledge that is generated from the limited financial support that is given to fundamental research in the muscular dystrophies would be beneficial for this field, other muscular diseases and the rare diseases field as a whole. But the barriers to progression are compounded by additional characteristics that are common to all other diseases and the culture of R&D and others that are unique to the field of muscular dystrophy.
One significant issue in knowledge generation in the muscular dystrophies is the genotypic diversity within each type that often prevents statistically relevant insights being obtained that can be leveraged into intervention development. This is because to obtain some level of relevant data the work has to be performed in an animal model that corresponds to the specific disease genotype. This means creating the model (often a mouse) through transgenic modification, and after stabilising the model, assessing if the genotypic change generates a disease phenotype that corresponds to the human form of disease. On the proviso that a comprehensive understanding of the disease progression and phenotype is understood in the human.
Pre-clinical modelling is used to generate data that show a corrective effect, levels of toxicity, intervention metabolism and potential dosing. After generation of the comprehensive dossier for review, a positive ethical review board will then permit a phase I testing of the drug in humans. The aim is to define if the considered therapeutic dose is toxic to a healthy human. If it is confirmed that the therapeutic does not harm a human, it is then approved to test in a small population of patients if in addition to not harming the patient it confers some level of corrective effect (phase IIa). If positive, the study can be expanded to more patients (phase IIb). Positive data from this phase enable the larger scale phase III, efficacy study on large patient populations. For diabetes and CVD, the available patient population for recruitment is huge.
For muscular dystrophies it is not; this means that a substantial amount of evidence has to be generated from between 30 to 250 patients, if they correspond to the inclusion/exclusion criteria of the trial, which typically includes not taking other experimental interventions. Independent of whether a disease is rare or frequent, this is not possible. It would be impossible and likely rejected by market authorisation bodies if this approach was taken for a highly prevalent disease as an evidence collection method. Policy changes have occurred focusing on rare diseases to be more flexible on effect and patient numbers, but clinical trial design still hinges on an ‘all or nothing’ therapeutic effect from a single intervention. This does not correspond to the complexity of muscle tissue, the diversity between patients, the impact of comorbidities and the regenerative characteristics of muscle.
For fundamental researchers, specifically those in academia who perform most of the fundamental research operate in a ‘publish or perish’ professional environment. The nature of fundamental R&D is that >90% of the data generated, at first glance, is a negative result, and the space limitations in articles accepted for publication means that even very limited positive results are shown. A negative result being defined as an outcome that does not correspond to enabling a chosen question to be answered, it does not mean the data are useless or invaluable.
With such limited resources, financially, biologically and clinically, but with such a clear patient need, the field needs to reconsider how it best leverages its data, especially as there are not a high number of researchers active in muscular dystrophy, in comparison to cancer or cardiovascular diseases.
This could be resolved through a ‘research data’ database that can be accessed by all accredited researchers to enable searching other historical data from other sources to look for concepts that did not work to prevent wasteful repetition, or to look at the unpublished data with a new perspective to enable a different insight. This also needs to happen with clinical data, from those patients in trials to those having their disease history mapped, albeit with a greater ethical oversight. There are nearly 13,000 patients presently in global clinical trials for Limb Girdle, Beckers and Duchenne muscular dystrophy who will be generating what may first appear to be non-relevant data related to the defined outcomes, but it is very likely that in the context of age, disease progression, biometrics, comorbidity status, mental health status, population health characteristics as well as response to intervention, these data are going to massively inform the field and globally standardised clinical care pathways and patient biometric measurements.
The Internet has irrevocably changed the dynamics of scholarly communication and publishing. Consequently, we find it necessary to indicate, unambiguously, our definition of what we consider to be a published scientific work.
",metaTitle:"Prior Publication Policy",metaDescription:"Prior Publication Policy",metaKeywords:null,canonicalURL:"/page/prior-publication-policy",contentRaw:'[{"type":"htmlEditorComponent","content":"A significant number of working papers, early drafts, and similar work in progress are openly shared online between members of the scientific community. It has become common to announce one’s own research on a personal website or a blog to gather comments and suggestions from other researchers. Such works and online postings are, indeed, published in the sense that they are made publicly available. However, this does not mean that if submitted for publication by IntechOpen they are not original works. We differentiate between reviewed and non-reviewed works when determining whether a work is original and has been published in a scholarly sense or not.
\\n\\nThe significance of Peer Review cannot be overstated when it comes to defining, in our terms, what constitutes a published scientific work. Peer Review is widely considered to be the cornerstone of modern publishing processes and the key value-adding contribution to a scholarly manuscript that a publisher can make.
\\n\\nOther than the issue of originality, research misconduct is another major issue that all publishers have to address. IntechOpen’s Retraction & Correction Policy and various publication ethics guidelines identify both redundant publication and (self)plagiarism to fall within the definition of research misconduct, thus constituting grounds for rejection or the issue of a Retraction if the work has already been published.
\\n\\nIn order to facilitate the tracking of a manuscript’s publishing history and its development from its earliest draft to the manuscript submitted, we encourage Authors to disclose any instances of a manuscript’s prior publication, whether it be through a conference presentation, a newspaper article, a working paper publicly available in a repository or a blog post.
\\n\\nA note to the Academic Editor containing detailed information about a submitted manuscript’s previous public availability is the preferred means of reporting prior publication. This helps us determine if there are any earlier versions of a manuscript that should be disclosed to our readers or if any of those earlier versions should be cited and listed in a manuscript’s references.
\\n\\nSome basic information about the editorial treatment of different varieties of prior publication is laid out below:
\\n\\n1. CONFERENCE PAPERS & PRESENTATIONS
\\n\\nGiven that conference papers and presentations generally pass through some sort of peer or editorial review, we consider them to be published in the accepted scholarly sense, particularly if they are published as a part of conference proceedings.
\\n\\nAll submitted manuscripts originating from a previously published conference paper must contain at least 50% of new original content to be accepted for review and considered for publication.
\\n\\nAuthors are required to report any links their manuscript might have with their earlier conference papers and presentations in a note to the Academic Editor, as well as in the manuscript itself. Additionally, Authors should obtain any necessary permissions from the publisher of their conference paper if copyright transfer occurred during the publishing process. Failure to do so may prevent Us from publishing an otherwise worthy work.
\\n\\n2. NEWSPAPER & MAGAZINE ARTICLES
\\n\\nNewspaper and magazine articles usually do not pass through any extensive peer or editorial review and we do not consider them to be published in the scholarly sense. Articles appearing in newspapers and magazines rarely possess the depth and structure characteristic of scholarly articles.
\\n\\nSubmitted manuscripts stemming from a previous newspaper or magazine article will be accepted for review and considered for publication. However, Authors are strongly advised to report any such publication in an accompanying note to the External Editor.
\\n\\nAs with the conference papers and presentations, Authors should obtain any necessary permissions from the newspaper or magazine that published the work, and indicate that they have done so in a note to the External Editor.
\\n\\n3. GREY LITERATURE
\\n\\nWhite papers, working papers, technical reports and all other forms of papers which fall within the scope of the ‘Luxembourg definition’ of grey literature do not pass through any extensive peer or editorial review and we do not consider them to be published in the scholarly sense.
\\n\\nAlthough such papers are regularly made publicly available via personal websites and institutional repositories, their general purpose is to gather comments and feedback from Authors’ colleagues in order to further improve a manuscript intended for future publication.
\\n\\nWhen submitting their work, Authors are required to disclose the existence of any publicly available earlier drafts in a note to the Academic Editor. In cases where earlier drafts of the submitted version of the manuscript are publicly available, any overlap between the versions will generally not be considered an instance of self-plagiarism.
\\n\\n4. SOCIAL MEDIA, BLOG & MESSAGE BOARD POSTINGS
\\n\\nWe feel that social media, blogs and message boards are generally used with the same intention as grey literature, to formulate ideas for a manuscript and gather early feedback from like-minded researchers in order to improve a particular piece of work before submitting it for publication. Therefore, we do not consider such internet postings to be publication in the scholarly sense.
\\n\\nNevertheless, Authors are encouraged to disclose the existence of any internet postings in which they outline and describe their research or posted passages of their manuscripts in a note to the Academic Editor. Please note that we will not strictly enforce this request in the same way that we would instructions we consider to be part of our conditions of acceptance for publication. We understand that it may be difficult to keep track of all one’s internet postings in which the researcher´s current work might be mentioned.
\\n\\nIn cases where there is any overlap between the Author´s submitted manuscript and related internet postings, we will generally not consider it to be an instance of self-plagiarism. This also holds true for any co-Author as well.
\\n\\nFor more information on this policy please contact permissions@intechopen.com.
\\n\\nPolicy last updated: 2017-03-20
\\n"}]'},components:[{type:"htmlEditorComponent",content:'A significant number of working papers, early drafts, and similar work in progress are openly shared online between members of the scientific community. It has become common to announce one’s own research on a personal website or a blog to gather comments and suggestions from other researchers. Such works and online postings are, indeed, published in the sense that they are made publicly available. However, this does not mean that if submitted for publication by IntechOpen they are not original works. We differentiate between reviewed and non-reviewed works when determining whether a work is original and has been published in a scholarly sense or not.
\n\nThe significance of Peer Review cannot be overstated when it comes to defining, in our terms, what constitutes a published scientific work. Peer Review is widely considered to be the cornerstone of modern publishing processes and the key value-adding contribution to a scholarly manuscript that a publisher can make.
\n\nOther than the issue of originality, research misconduct is another major issue that all publishers have to address. IntechOpen’s Retraction & Correction Policy and various publication ethics guidelines identify both redundant publication and (self)plagiarism to fall within the definition of research misconduct, thus constituting grounds for rejection or the issue of a Retraction if the work has already been published.
\n\nIn order to facilitate the tracking of a manuscript’s publishing history and its development from its earliest draft to the manuscript submitted, we encourage Authors to disclose any instances of a manuscript’s prior publication, whether it be through a conference presentation, a newspaper article, a working paper publicly available in a repository or a blog post.
\n\nA note to the Academic Editor containing detailed information about a submitted manuscript’s previous public availability is the preferred means of reporting prior publication. This helps us determine if there are any earlier versions of a manuscript that should be disclosed to our readers or if any of those earlier versions should be cited and listed in a manuscript’s references.
\n\nSome basic information about the editorial treatment of different varieties of prior publication is laid out below:
\n\n1. CONFERENCE PAPERS & PRESENTATIONS
\n\nGiven that conference papers and presentations generally pass through some sort of peer or editorial review, we consider them to be published in the accepted scholarly sense, particularly if they are published as a part of conference proceedings.
\n\nAll submitted manuscripts originating from a previously published conference paper must contain at least 50% of new original content to be accepted for review and considered for publication.
\n\nAuthors are required to report any links their manuscript might have with their earlier conference papers and presentations in a note to the Academic Editor, as well as in the manuscript itself. Additionally, Authors should obtain any necessary permissions from the publisher of their conference paper if copyright transfer occurred during the publishing process. Failure to do so may prevent Us from publishing an otherwise worthy work.
\n\n2. NEWSPAPER & MAGAZINE ARTICLES
\n\nNewspaper and magazine articles usually do not pass through any extensive peer or editorial review and we do not consider them to be published in the scholarly sense. Articles appearing in newspapers and magazines rarely possess the depth and structure characteristic of scholarly articles.
\n\nSubmitted manuscripts stemming from a previous newspaper or magazine article will be accepted for review and considered for publication. However, Authors are strongly advised to report any such publication in an accompanying note to the External Editor.
\n\nAs with the conference papers and presentations, Authors should obtain any necessary permissions from the newspaper or magazine that published the work, and indicate that they have done so in a note to the External Editor.
\n\n3. GREY LITERATURE
\n\nWhite papers, working papers, technical reports and all other forms of papers which fall within the scope of the ‘Luxembourg definition’ of grey literature do not pass through any extensive peer or editorial review and we do not consider them to be published in the scholarly sense.
\n\nAlthough such papers are regularly made publicly available via personal websites and institutional repositories, their general purpose is to gather comments and feedback from Authors’ colleagues in order to further improve a manuscript intended for future publication.
\n\nWhen submitting their work, Authors are required to disclose the existence of any publicly available earlier drafts in a note to the Academic Editor. In cases where earlier drafts of the submitted version of the manuscript are publicly available, any overlap between the versions will generally not be considered an instance of self-plagiarism.
\n\n4. SOCIAL MEDIA, BLOG & MESSAGE BOARD POSTINGS
\n\nWe feel that social media, blogs and message boards are generally used with the same intention as grey literature, to formulate ideas for a manuscript and gather early feedback from like-minded researchers in order to improve a particular piece of work before submitting it for publication. Therefore, we do not consider such internet postings to be publication in the scholarly sense.
\n\nNevertheless, Authors are encouraged to disclose the existence of any internet postings in which they outline and describe their research or posted passages of their manuscripts in a note to the Academic Editor. Please note that we will not strictly enforce this request in the same way that we would instructions we consider to be part of our conditions of acceptance for publication. We understand that it may be difficult to keep track of all one’s internet postings in which the researcher´s current work might be mentioned.
\n\nIn cases where there is any overlap between the Author´s submitted manuscript and related internet postings, we will generally not consider it to be an instance of self-plagiarism. This also holds true for any co-Author as well.
\n\nFor more information on this policy please contact permissions@intechopen.com.
\n\nPolicy last updated: 2017-03-20
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[],filtersByRegion:[],offset:0,limit:12,total:null},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"1",sort:"dateEndThirdStepPublish",topicId:"6"},books:[{type:"book",id:"11645",title:"Neural Tube Defects",subtitle:null,isOpenForSubmission:!0,hash:"08d6ba70d97767769a97cfeeb52dac78",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11645.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12214",title:"Phagocytosis",subtitle:null,isOpenForSubmission:!0,hash:"79d7747d6e3aa6a3623ab710a7634588",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12214.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12216",title:"Cell Proliferation",subtitle:null,isOpenForSubmission:!0,hash:"d5e37e8c90c4c6cb33c25d4445574ac0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12216.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12217",title:"Protein Interactions",subtitle:null,isOpenForSubmission:!0,hash:"8514f8e3d3dd0e22e87b0c4c84a6cc3a",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12217.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12218",title:"Phytochemicals",subtitle:null,isOpenForSubmission:!0,hash:"8cb2e6bb3d9c717bb8dc44e35ed774c2",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12218.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12174",title:"Genetic Polymorphisms",subtitle:null,isOpenForSubmission:!0,hash:"5922df051a2033c98d2edfb31dd84f8c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12174.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12177",title:"Epigenetics",subtitle:null,isOpenForSubmission:!0,hash:"185b00910074e8beeedd2276900a911a",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12177.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12310",title:"Advances in Transcriptome Analysis",subtitle:null,isOpenForSubmission:!0,hash:"9b0d98cf9a47e93524dbaa2eedbbcf46",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12310.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12332",title:"Resveratrol - Recent Advances, Application, and Therapeutic Potential",subtitle:null,isOpenForSubmission:!0,hash:"3b7fe05be184ecb8d7d79fda19259829",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12332.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12333",title:"Alkaloids",subtitle:null,isOpenForSubmission:!0,hash:"50ba29b67f4b54e2e38088c223b35305",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12333.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12368",title:"Histones",subtitle:null,isOpenForSubmission:!0,hash:"b6890021008f436dcc47bf04c8e57b34",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12368.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12369",title:"Ubiquitin",subtitle:null,isOpenForSubmission:!0,hash:"5a82dedbd96e152e777bd10a244e5d57",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12369.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:42},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:12},{group:"topic",caption:"Business, Management and Economics",value:7,count:7},{group:"topic",caption:"Chemistry",value:8,count:17},{group:"topic",caption:"Computer and Information Science",value:9,count:18},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:18},{group:"topic",caption:"Engineering",value:11,count:46},{group:"topic",caption:"Environmental Sciences",value:12,count:7},{group:"topic",caption:"Immunology and Microbiology",value:13,count:11},{group:"topic",caption:"Materials Science",value:14,count:14},{group:"topic",caption:"Mathematics",value:15,count:6},{group:"topic",caption:"Medicine",value:16,count:107},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:2},{group:"topic",caption:"Neuroscience",value:18,count:7},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:11},{group:"topic",caption:"Physics",value:20,count:4},{group:"topic",caption:"Psychology",value:21,count:8},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:32},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:12},popularBooks:{featuredBooks:[],offset:0,limit:12,total:null},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",publishedDate:"April 28th 2022",numberOfDownloads:3665,editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1713,editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",publishedDate:"April 28th 2022",numberOfDownloads:2481,editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1107,editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3307,editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3266,editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1868,editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",publishedDate:"May 4th 2022",numberOfDownloads:856,editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1704,editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",publishedDate:"March 16th 2022",numberOfDownloads:7489,editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"10251",title:"Plankton Communities",subtitle:null,isOpenForSubmission:!1,hash:"e11e441ca2d2d5f631b1b4704505cfb6",slug:"plankton-communities",bookSignature:"Leonel Pereira and Ana Marta Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/10251.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"279788",title:"Dr.",name:"Leonel",middleName:null,surname:"Pereira",slug:"leonel-pereira",fullName:"Leonel Pereira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10830",title:"Animal Feed Science and Nutrition",subtitle:"Production, Health and Environment",isOpenForSubmission:!1,hash:"79944fc8fbbaa329aed6fde388154832",slug:"animal-feed-science-and-nutrition-production-health-and-environment",bookSignature:"Amlan Kumar Patra",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"310962",title:"Dr.",name:"Amlan",middleName:"Kumar",surname:"Patra",slug:"amlan-patra",fullName:"Amlan Patra"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10853",title:"Recent Advances in Polynomials",subtitle:null,isOpenForSubmission:!1,hash:"9e8671bae09ccaa8b8e276c639a737fc",slug:"recent-advances-in-polynomials",bookSignature:"Kamal Shah",coverURL:"https://cdn.intechopen.com/books/images_new/10853.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10871",title:"Computed-Tomography (CT) Scan",subtitle:null,isOpenForSubmission:!1,hash:"966d8cf74fa27eea1b9cbc9a6ee94993",slug:"computed-tomography-ct-scan",bookSignature:"Reda R. Gharieb",coverURL:"https://cdn.intechopen.com/books/images_new/10871.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"225387",title:"Prof.",name:"Reda R.",middleName:"R.",surname:"Gharieb",slug:"reda-r.-gharieb",fullName:"Reda R. Gharieb"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10903",title:"Genetically Modified Plants and Beyond",subtitle:null,isOpenForSubmission:!1,hash:"4d7ed4faab99c92cd4d676dc86501df9",slug:"genetically-modified-plants-and-beyond",bookSignature:"Idah Sithole Niang",coverURL:"https://cdn.intechopen.com/books/images_new/10903.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"90172",title:"Prof.",name:"Idah",middleName:null,surname:"Sithole-Niang",slug:"idah-sithole-niang",fullName:"Idah Sithole-Niang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10904",title:"Fusarium",subtitle:"An Overview of the Genus",isOpenForSubmission:!1,hash:"49d9063e43f94bd1517d65fbc58b93c3",slug:"fusarium-an-overview-of-the-genus",bookSignature:"Seyed Mahyar Mirmajlessi",coverURL:"https://cdn.intechopen.com/books/images_new/10904.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"100573",title:"Dr.",name:"Seyed Mahyar",middleName:null,surname:"Mirmajlessi",slug:"seyed-mahyar-mirmajlessi",fullName:"Seyed Mahyar Mirmajlessi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10654",title:"Brain-Computer Interface",subtitle:null,isOpenForSubmission:!1,hash:"a5308884068cc53ed31c6baba756857f",slug:"brain-computer-interface",bookSignature:"Vahid Asadpour",coverURL:"https://cdn.intechopen.com/books/images_new/10654.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"165328",title:"Dr.",name:"Vahid",middleName:null,surname:"Asadpour",slug:"vahid-asadpour",fullName:"Vahid Asadpour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10676",title:"Recent Applications in Graph Theory",subtitle:null,isOpenForSubmission:!1,hash:"900c60742d224080732bd16bd25ccba8",slug:"recent-applications-in-graph-theory",bookSignature:"Harun Pirim",coverURL:"https://cdn.intechopen.com/books/images_new/10676.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"146092",title:"Dr.",name:"Harun",middleName:null,surname:"Pirim",slug:"harun-pirim",fullName:"Harun Pirim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11196",title:"New Updates in E-Learning",subtitle:null,isOpenForSubmission:!1,hash:"6afaadf68e2a0a4b370ac5ceb5ca89c6",slug:"new-updates-in-e-learning",bookSignature:"Eduard Babulak",coverURL:"https://cdn.intechopen.com/books/images_new/11196.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"10086",title:"Prof.",name:"Eduard",middleName:null,surname:"Babulak",slug:"eduard-babulak",fullName:"Eduard Babulak"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9974",title:"E-Learning and Digital Education in the Twenty-First Century",subtitle:null,isOpenForSubmission:!1,hash:"88b58d66e975df20425fc1dfd22d53aa",slug:"e-learning-and-digital-education-in-the-twenty-first-century",bookSignature:"M. Mahruf C. Shohel",coverURL:"https://cdn.intechopen.com/books/images_new/9974.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"94099",title:"Dr.",name:"M. Mahruf C.",middleName:null,surname:"Shohel",slug:"m.-mahruf-c.-shohel",fullName:"M. Mahruf C. Shohel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"1037",title:"Immunogenetics",slug:"immunogenetics",parent:{id:"184",title:"Immunology, Allergology and Rheumatology",slug:"immunology-allergology-and-rheumatology"},numberOfBooks:3,numberOfSeries:0,numberOfAuthorsAndEditors:80,numberOfWosCitations:24,numberOfCrossrefCitations:22,numberOfDimensionsCitations:50,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"1037",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"7475",title:"Immunogenetics",subtitle:null,isOpenForSubmission:!1,hash:"dd50ca8b9158dc45b6b23fcae43d1daa",slug:"immunogenetics",bookSignature:"Nima Rezaei",coverURL:"https://cdn.intechopen.com/books/images_new/7475.jpg",editedByType:"Edited by",editors:[{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3207",title:"Genes and Autoimmunity",subtitle:"Intracellular Signaling and Microbiome Contribution",isOpenForSubmission:!1,hash:"a3f99e5e0aaeb582b7c17c19982015f7",slug:"genes-and-autoimmunity-intracellular-signaling-and-microbiome-contribution",bookSignature:"Spaska Angelova Stanilova",coverURL:"https://cdn.intechopen.com/books/images_new/3207.jpg",editedByType:"Edited by",editors:[{id:"69749",title:"Prof.",name:"Spaska",middleName:null,surname:"Stanilova",slug:"spaska-stanilova",fullName:"Spaska Stanilova"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2517",title:"Autoimmune Diseases",subtitle:"Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies",isOpenForSubmission:!1,hash:"a212e9ae7688cbe123bfb1936b3e3cd4",slug:"autoimmune-diseases-contributing-factors-specific-cases-of-autoimmune-diseases-and-stem-cell-and-other-therapies",bookSignature:"James Chan",coverURL:"https://cdn.intechopen.com/books/images_new/2517.jpg",editedByType:"Edited by",editors:[{id:"135686",title:"Dr.",name:"James",middleName:null,surname:"Chan",slug:"james-chan",fullName:"James Chan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:3,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"60651",doi:"10.5772/intechopen.75951",title:"Immunoassay Techniques Highlighting Biomarkers in Immunogenetic Diseases",slug:"immunoassay-techniques-highlighting-biomarkers-in-immunogenetic-diseases",totalDownloads:1559,totalCrossrefCites:2,totalDimensionsCites:9,abstract:"Diagnosis of autoimmune diseases is crucial for the clinician and the patient alike. The immunoassay techniques most commonly used for this purpose are immunohistochemistry, ELISA, and Western blotting. For the detection of more specific biomarkers or the discovery of new ones for diagnostic purposes and as therapeutic targets, microarray techniques are increasingly used, for example, protein microarray, Luminex, and in recent years, surface plasmon resonance imaging. All of these technologies have undergone changes over time, making them easier to use. Similar technologies have been invented but responding to specific requirements for both diagnostic and research purposes. The goals are to study more analytes in the same sample, in a shorter time, and with increased accuracy. The reproducibility and reliability of the results are also a target pursued by manufacturers. In this chapter, we present these technologies and their utility in the diagnosis of immunogenetic diseases.",book:{id:"7475",slug:"immunogenetics",title:"Immunogenetics",fullTitle:"Immunogenetics"},signatures:"Emilia Manole, Alexandra E. Bastian, Ionela D. Popescu, Carolina Constantin, Simona Mihai, Gisela F. Gaina, Elena Codrici and Monica T. Neagu",authors:[{id:"52215",title:"Prof.",name:"Monica",middleName:null,surname:"Teodora Neagu",slug:"monica-teodora-neagu",fullName:"Monica Teodora Neagu"},{id:"52218",title:"Dr.",name:"Carolina",middleName:null,surname:"Constantin",slug:"carolina-constantin",fullName:"Carolina Constantin"},{id:"89397",title:"Dr.",name:"Emilia",middleName:null,surname:"Manole",slug:"emilia-manole",fullName:"Emilia Manole"},{id:"216223",title:"Dr.",name:"Elena",middleName:null,surname:"Codrici",slug:"elena-codrici",fullName:"Elena Codrici"},{id:"216226",title:"Dr.",name:"Ionela Daniela",middleName:null,surname:"Popescu",slug:"ionela-daniela-popescu",fullName:"Ionela Daniela Popescu"},{id:"216227",title:"Dr.",name:"Simona",middleName:null,surname:"Mihai",slug:"simona-mihai",fullName:"Simona Mihai"},{id:"233495",title:"Dr.",name:"Alexandra",middleName:null,surname:"Eugenia Bastian",slug:"alexandra-eugenia-bastian",fullName:"Alexandra Eugenia Bastian"},{id:"242747",title:"Dr.",name:"Gisela",middleName:null,surname:"Gaina",slug:"gisela-gaina",fullName:"Gisela Gaina"}]},{id:"43387",doi:"10.5772/54218",title:"Biomarkers of Inflammatory Arthritis and Proteomics",slug:"biomarkers-of-inflammatory-arthritis-and-proteomics",totalDownloads:2767,totalCrossrefCites:0,totalDimensionsCites:4,abstract:null,book:{id:"3207",slug:"genes-and-autoimmunity-intracellular-signaling-and-microbiome-contribution",title:"Genes and Autoimmunity",fullTitle:"Genes and Autoimmunity - Intracellular Signaling and Microbiome Contribution"},signatures:"Opeyemi S. Ademowo, Lisa Staunton, Oliver FitzGerald and Stephen R. Pennington",authors:[{id:"89766",title:"Prof.",name:"Stephen",middleName:null,surname:"Pennington",slug:"stephen-pennington",fullName:"Stephen Pennington"},{id:"161739",title:"Dr.",name:"Opeyemi Stella",middleName:null,surname:"Ademowo",slug:"opeyemi-stella-ademowo",fullName:"Opeyemi Stella Ademowo"},{id:"161740",title:"Dr.",name:"Oliver",middleName:null,surname:"FitzGerald",slug:"oliver-fitzgerald",fullName:"Oliver FitzGerald"},{id:"167692",title:"Dr.",name:"Lisa",middleName:null,surname:"Staunton",slug:"lisa-staunton",fullName:"Lisa Staunton"}]},{id:"38027",doi:"10.5772/48161",title:"Central Nervous System Resident Cells in Neuroinflammation: A Brave New World.",slug:"central-nervous-system-resident-cells-in-neuroinflammation-a-brave-new-world-",totalDownloads:1884,totalCrossrefCites:2,totalDimensionsCites:4,abstract:null,book:{id:"2517",slug:"autoimmune-diseases-contributing-factors-specific-cases-of-autoimmune-diseases-and-stem-cell-and-other-therapies",title:"Autoimmune Diseases",fullTitle:"Autoimmune Diseases - Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies"},signatures:"J.P.S. Peron, D. Oliveira, W. N. Brandão, A. Fickinger, A. P. Ligeiro de Oliveira, L. V. Rizzo and N.O.S. Câmara",authors:[{id:"139849",title:"PhD.",name:"Jean Pierre",middleName:null,surname:"Peron",slug:"jean-pierre-peron",fullName:"Jean Pierre Peron"}]},{id:"63838",doi:"10.5772/intechopen.80731",title:"Dynamic Interaction between Immune Escape Mechanism and HLA-Ib Regulation",slug:"dynamic-interaction-between-immune-escape-mechanism-and-hla-ib-regulation",totalDownloads:935,totalCrossrefCites:4,totalDimensionsCites:4,abstract:"HLA molecules scan the intracellular proteome and present self- or non-self-peptides to immune effector cells. HLA-Ia (HLA-A, HLA-B and HLA-C) are the most polymorphic genes, resulting in various numbers of allelic variants expressed on the surface of almost all nucleated cells. In contrast to HLA-Ia molecules that activate the immune system during pathogenic invasion, the marginal polymorphic HLA-Ib molecules (HLA-E, HLA-F and HLA-G) are upregulated during pathogenic episodes and mediate immune tolerance. A fine tuning between downregulation of HLA-Ia and upregulation of HLA-Ib can be observed through immunological episodes that require to remain unrecognized by immune effector cells. While HLA-Ia molecules collaborate by presenting a wide range of peptides, every HLA-Ib molecule is highly specialized in its protective immune function and seems to be restricted in the presentation of peptides. Additionally, Ia molecules are expressed ubiquitously while the expression of HLA-Ib molecules is strictly restricted to certain tissues and occurs instantly on demand of the cells/tissue that attempt to be hidden from the immune system. The more knowledge becomes available for the function of HLA-Ib molecules; the question emerges if the molecular typing of HLA-Ib molecules would be reasonable to take a decision post treatment for personalized cellular therapies.",book:{id:"7475",slug:"immunogenetics",title:"Immunogenetics",fullTitle:"Immunogenetics"},signatures:"Gia-Gia Toni Ho, Funmilola Heinen, Florian Stieglitz, Rainer Blasczyk and Christina Bade-Döding",authors:[{id:"72037",title:"Prof.",name:"Rainer",middleName:null,surname:"Blasczyk",slug:"rainer-blasczyk",fullName:"Rainer Blasczyk"},{id:"169291",title:"Dr.",name:"Christina",middleName:null,surname:"Bade-Doeding",slug:"christina-bade-doeding",fullName:"Christina Bade-Doeding"},{id:"268556",title:"BSc.",name:"Funmilola",middleName:null,surname:"Heinen",slug:"funmilola-heinen",fullName:"Funmilola Heinen"},{id:"268557",title:"MSc.",name:"Gia-Gia Toni",middleName:null,surname:"Ho",slug:"gia-gia-toni-ho",fullName:"Gia-Gia Toni Ho"},{id:"268558",title:"M.Sc.",name:"Florian",middleName:null,surname:"Stieglitz",slug:"florian-stieglitz",fullName:"Florian Stieglitz"}]},{id:"66722",doi:"10.5772/intechopen.85505",title:"Introductory Chapter: Immunogenetics",slug:"introductory-chapter-immunogenetics",totalDownloads:1231,totalCrossrefCites:3,totalDimensionsCites:4,abstract:null,book:{id:"7475",slug:"immunogenetics",title:"Immunogenetics",fullTitle:"Immunogenetics"},signatures:"Amene Saghazadeh and Nima Rezaei",authors:[{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei"},{id:"301367",title:"Dr.",name:"Amene",middleName:null,surname:"Saghazadeh",slug:"amene-saghazadeh",fullName:"Amene Saghazadeh"}]}],mostDownloadedChaptersLast30Days:[{id:"60651",title:"Immunoassay Techniques Highlighting Biomarkers in Immunogenetic Diseases",slug:"immunoassay-techniques-highlighting-biomarkers-in-immunogenetic-diseases",totalDownloads:1559,totalCrossrefCites:2,totalDimensionsCites:9,abstract:"Diagnosis of autoimmune diseases is crucial for the clinician and the patient alike. The immunoassay techniques most commonly used for this purpose are immunohistochemistry, ELISA, and Western blotting. For the detection of more specific biomarkers or the discovery of new ones for diagnostic purposes and as therapeutic targets, microarray techniques are increasingly used, for example, protein microarray, Luminex, and in recent years, surface plasmon resonance imaging. All of these technologies have undergone changes over time, making them easier to use. Similar technologies have been invented but responding to specific requirements for both diagnostic and research purposes. The goals are to study more analytes in the same sample, in a shorter time, and with increased accuracy. The reproducibility and reliability of the results are also a target pursued by manufacturers. In this chapter, we present these technologies and their utility in the diagnosis of immunogenetic diseases.",book:{id:"7475",slug:"immunogenetics",title:"Immunogenetics",fullTitle:"Immunogenetics"},signatures:"Emilia Manole, Alexandra E. Bastian, Ionela D. Popescu, Carolina Constantin, Simona Mihai, Gisela F. Gaina, Elena Codrici and Monica T. Neagu",authors:[{id:"52215",title:"Prof.",name:"Monica",middleName:null,surname:"Teodora Neagu",slug:"monica-teodora-neagu",fullName:"Monica Teodora Neagu"},{id:"52218",title:"Dr.",name:"Carolina",middleName:null,surname:"Constantin",slug:"carolina-constantin",fullName:"Carolina Constantin"},{id:"89397",title:"Dr.",name:"Emilia",middleName:null,surname:"Manole",slug:"emilia-manole",fullName:"Emilia Manole"},{id:"216223",title:"Dr.",name:"Elena",middleName:null,surname:"Codrici",slug:"elena-codrici",fullName:"Elena Codrici"},{id:"216226",title:"Dr.",name:"Ionela Daniela",middleName:null,surname:"Popescu",slug:"ionela-daniela-popescu",fullName:"Ionela Daniela Popescu"},{id:"216227",title:"Dr.",name:"Simona",middleName:null,surname:"Mihai",slug:"simona-mihai",fullName:"Simona Mihai"},{id:"233495",title:"Dr.",name:"Alexandra",middleName:null,surname:"Eugenia Bastian",slug:"alexandra-eugenia-bastian",fullName:"Alexandra Eugenia Bastian"},{id:"242747",title:"Dr.",name:"Gisela",middleName:null,surname:"Gaina",slug:"gisela-gaina",fullName:"Gisela Gaina"}]},{id:"66722",title:"Introductory Chapter: Immunogenetics",slug:"introductory-chapter-immunogenetics",totalDownloads:1231,totalCrossrefCites:3,totalDimensionsCites:4,abstract:null,book:{id:"7475",slug:"immunogenetics",title:"Immunogenetics",fullTitle:"Immunogenetics"},signatures:"Amene Saghazadeh and Nima Rezaei",authors:[{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei"},{id:"301367",title:"Dr.",name:"Amene",middleName:null,surname:"Saghazadeh",slug:"amene-saghazadeh",fullName:"Amene Saghazadeh"}]},{id:"43369",title:"Microbiome and Autoimmunity",slug:"microbiome-and-autoimmunity",totalDownloads:1937,totalCrossrefCites:0,totalDimensionsCites:0,abstract:null,book:{id:"3207",slug:"genes-and-autoimmunity-intracellular-signaling-and-microbiome-contribution",title:"Genes and Autoimmunity",fullTitle:"Genes and Autoimmunity - Intracellular Signaling and Microbiome Contribution"},signatures:"Natalie Cherepahina, Zaur Shogenov, Mariya Bocharova, Murat Agirov, Jamilyia Tabaksoeva, Mikhail Paltsev and Sergey Suchkov",authors:[{id:"49135",title:"Dr.",name:"Natalie",middleName:null,surname:"Cherepahina",slug:"natalie-cherepahina",fullName:"Natalie Cherepahina"},{id:"49136",title:"Dr.",name:"Jamiliya",middleName:null,surname:"Tabaksoeva",slug:"jamiliya-tabaksoeva",fullName:"Jamiliya Tabaksoeva"},{id:"49137",title:"Dr.",name:"Murat",middleName:null,surname:"Agirov",slug:"murat-agirov",fullName:"Murat Agirov"},{id:"155909",title:"Prof.",name:"Sergey",middleName:null,surname:"Suchkov",slug:"sergey-suchkov",fullName:"Sergey Suchkov"},{id:"158987",title:"BSc.",name:"Mariya",middleName:null,surname:"Bocharova",slug:"mariya-bocharova",fullName:"Mariya Bocharova"},{id:"160426",title:"Dr.",name:"Zaur",middleName:null,surname:"Shogenov",slug:"zaur-shogenov",fullName:"Zaur Shogenov"},{id:"160429",title:"Prof.",name:"Mikhail",middleName:null,surname:"Paltsev",slug:"mikhail-paltsev",fullName:"Mikhail Paltsev"}]},{id:"43367",title:"Immune Synapses Between Lymphocytes and Target Cells in Autoimmune Thyroid Diseases",slug:"immune-synapses-between-lymphocytes-and-target-cells-in-autoimmune-thyroid-diseases",totalDownloads:1996,totalCrossrefCites:0,totalDimensionsCites:0,abstract:null,book:{id:"3207",slug:"genes-and-autoimmunity-intracellular-signaling-and-microbiome-contribution",title:"Genes and Autoimmunity",fullTitle:"Genes and Autoimmunity - Intracellular Signaling and Microbiome Contribution"},signatures:"Iwona Ben-Skowronek and Roman Ciechanek",authors:[{id:"37123",title:"Dr",name:"Iwona",middleName:null,surname:"Ben-Skowronek",slug:"iwona-ben-skowronek",fullName:"Iwona Ben-Skowronek"}]},{id:"38017",title:"New Therapeutic Challenges in Autoimmune Diseases",slug:"new-therapeutic-challenges-in-autoimmune-diseases",totalDownloads:3153,totalCrossrefCites:0,totalDimensionsCites:4,abstract:null,book:{id:"2517",slug:"autoimmune-diseases-contributing-factors-specific-cases-of-autoimmune-diseases-and-stem-cell-and-other-therapies",title:"Autoimmune Diseases",fullTitle:"Autoimmune Diseases - Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies"},signatures:"Eun Wha Choi",authors:[{id:"140501",title:"Dr.",name:"Eun Wha",middleName:null,surname:"Choi",slug:"eun-wha-choi",fullName:"Eun Wha Choi"}]}],onlineFirstChaptersFilter:{topicId:"1037",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:0,limit:8,total:null},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:287,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:107,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:10,numberOfPublishedChapters:103,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:12,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:10,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"7",title:"Biomedical Engineering",doi:"10.5772/intechopen.71985",issn:"2631-5343",scope:"Biomedical Engineering is one of the fastest-growing interdisciplinary branches of science and industry. The combination of electronics and computer science with biology and medicine has improved patient diagnosis, reduced rehabilitation time, and helped to facilitate a better quality of life. Nowadays, all medical imaging devices, medical instruments, or new laboratory techniques result from the cooperation of specialists in various fields. The series of Biomedical Engineering books covers such areas of knowledge as chemistry, physics, electronics, medicine, and biology. This series is intended for doctors, engineers, and scientists involved in biomedical engineering or those wanting to start working in this field.",coverUrl:"https://cdn.intechopen.com/series/covers/7.jpg",latestPublicationDate:"May 13th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:12,editor:{id:"50150",title:"Prof.",name:"Robert",middleName:null,surname:"Koprowski",slug:"robert-koprowski",fullName:"Robert Koprowski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTYNQA4/Profile_Picture_1630478535317",biography:"Robert Koprowski, MD (1997), PhD (2003), Habilitation (2015), is an employee of the University of Silesia, Poland, Institute of Computer Science, Department of Biomedical Computer Systems. For 20 years, he has studied the analysis and processing of biomedical images, emphasizing the full automation of measurement for a large inter-individual variability of patients. Dr. Koprowski has authored more than a hundred research papers with dozens in impact factor (IF) journals and has authored or co-authored six books. Additionally, he is the author of several national and international patents in the field of biomedical devices and imaging. Since 2011, he has been a reviewer of grants and projects (including EU projects) in biomedical engineering.",institutionString:null,institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:3,paginationItems:[{id:"7",title:"Bioinformatics and Medical Informatics",coverUrl:"https://cdn.intechopen.com/series_topics/covers/7.jpg",isOpenForSubmission:!0,editor:{id:"351533",title:"Dr.",name:"Slawomir",middleName:null,surname:"Wilczynski",slug:"slawomir-wilczynski",fullName:"Slawomir Wilczynski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000035U1loQAC/Profile_Picture_1630074514792",biography:"Professor Sławomir Wilczyński, Head of the Chair of Department of Basic Biomedical Sciences, Faculty of Pharmaceutical Sciences, Medical University of Silesia in Katowice, Poland. His research interests are focused on modern imaging methods used in medicine and pharmacy, including in particular hyperspectral imaging, dynamic thermovision analysis, high-resolution ultrasound, as well as other techniques such as EPR, NMR and hemispheric directional reflectance. Author of over 100 scientific works, patents and industrial designs. Expert of the Polish National Center for Research and Development, Member of the Investment Committee in the Bridge Alfa NCBiR program, expert of the Polish Ministry of Funds and Regional Policy, Polish Medical Research Agency. Editor-in-chief of the journal in the field of aesthetic medicine and dermatology - Aesthetica.",institutionString:null,institution:{name:"Medical University of Silesia",institutionURL:null,country:{name:"Poland"}}},editorTwo:null,editorThree:null},{id:"8",title:"Bioinspired Technology and Biomechanics",coverUrl:"https://cdn.intechopen.com/series_topics/covers/8.jpg",isOpenForSubmission:!0,editor:{id:"144937",title:"Prof.",name:"Adriano",middleName:"De Oliveira",surname:"Andrade",slug:"adriano-andrade",fullName:"Adriano Andrade",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRC8QQAW/Profile_Picture_1625219101815",biography:"Dr. Adriano de Oliveira Andrade graduated in Electrical Engineering at the Federal University of Goiás (Brazil) in 1997. He received his MSc and PhD in Biomedical Engineering respectively from the Federal University of Uberlândia (UFU, Brazil) in 2000 and from the University of Reading (UK) in 2005. He completed a one-year Post-Doctoral Fellowship awarded by the DFAIT (Foreign Affairs and International Trade Canada) at the Institute of Biomedical Engineering of the University of New Brunswick (Canada) in 2010. Currently, he is Professor in the Faculty of Electrical Engineering (UFU). He has authored and co-authored more than 200 peer-reviewed publications in Biomedical Engineering. He has been a researcher of The National Council for Scientific and Technological Development (CNPq-Brazil) since 2009. He has served as an ad-hoc consultant for CNPq, CAPES (Coordination for the Improvement of Higher Education Personnel), FINEP (Brazilian Innovation Agency), and other funding bodies on several occasions. He was the Secretary of the Brazilian Society of Biomedical Engineering (SBEB) from 2015 to 2016, President of SBEB (2017-2018) and Vice-President of SBEB (2019-2020). He was the head of the undergraduate program in Biomedical Engineering of the Federal University of Uberlândia (2015 - June/2019) and the head of the Centre for Innovation and Technology Assessment in Health (NIATS/UFU) since 2010. He is the head of the Postgraduate Program in Biomedical Engineering (UFU, July/2019 - to date). He was the secretary of the Parkinson's Disease Association of Uberlândia (2018-2019). Dr. Andrade's primary area of research is focused towards getting information from the neuromuscular system to understand its strategies of organization, adaptation and controlling in the context of motor neuron diseases. His research interests include Biomedical Signal Processing and Modelling, Assistive Technology, Rehabilitation Engineering, Neuroengineering and Parkinson's Disease.",institutionString:null,institution:{name:"Federal University of Uberlândia",institutionURL:null,country:{name:"Brazil"}}},editorTwo:null,editorThree:null},{id:"9",title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering",coverUrl:"https://cdn.intechopen.com/series_topics/covers/9.jpg",isOpenForSubmission:!0,editor:{id:"126286",title:"Dr.",name:"Luis",middleName:"Jesús",surname:"Villarreal-Gómez",slug:"luis-villarreal-gomez",fullName:"Luis Villarreal-Gómez",profilePictureURL:"https://mts.intechopen.com/storage/users/126286/images/system/126286.jpg",biography:"Dr. Luis Villarreal is a research professor from the Facultad de Ciencias de la Ingeniería y Tecnología, Universidad Autónoma de Baja California, Tijuana, Baja California, México. Dr. Villarreal is the editor in chief and founder of the Revista de Ciencias Tecnológicas (RECIT) (https://recit.uabc.mx/) and is a member of several editorial and reviewer boards for numerous international journals. He has published more than thirty international papers and reviewed more than ninety-two manuscripts. His research interests include biomaterials, nanomaterials, bioengineering, biosensors, drug delivery systems, and tissue engineering.",institutionString:null,institution:{name:"Autonomous University of Baja California",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null}]},overviewPageOFChapters:{paginationCount:17,paginationItems:[{id:"81751",title:"NanoBioSensors: From Electrochemical Sensors Improvement to Theranostic Applications",doi:"10.5772/intechopen.102552",signatures:"Anielle C.A. Silva, Eliete A. Alvin, Lais S. de Jesus, Caio C.L. de França, Marílya P.G. da Silva, Samaysa L. Lins, Diógenes Meneses, Marcela R. Lemes, Rhanoica O. Guerra, Marcos V. da Silva, Carlo J.F. de Oliveira, Virmondes Rodrigues Junior, Renata M. Etchebehere, Fabiane C. de Abreu, Bruno G. Lucca, Sanívia A.L. Pereira, Rodrigo C. Rosa and Noelio O. Dantas",slug:"nanobiosensors-from-electrochemical-sensors-improvement-to-theranostic-applications",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81766",title:"Evolution of Organoids in Oncology",doi:"10.5772/intechopen.104251",signatures:"Allen Thayakumar Basanthakumar, Janitha Chandrasekhar Darlybai and Jyothsna Ganesh",slug:"evolution-of-organoids-in-oncology",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Organoids",coverURL:"https://cdn.intechopen.com/books/images_new/11430.jpg",subseries:null}},{id:"81678",title:"Developmental Studies on Practical Enzymatic Phosphate Ion Biosensors and Microbial BOD Biosensors, and New Insights into the Future Perspectives of These Biosensor Fields",doi:"10.5772/intechopen.104377",signatures:"Hideaki Nakamura",slug:"developmental-studies-on-practical-enzymatic-phosphate-ion-biosensors-and-microbial-bod-biosensors-a",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Hideaki",surname:"Nakamura"}],book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81547",title:"Organoids and Commercialization",doi:"10.5772/intechopen.104706",signatures:"Anubhab Mukherjee, Aprajita Sinha, Maheshree Maibam, Bharti Bisht and Manash K. Paul",slug:"organoids-and-commercialization",totalDownloads:31,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Organoids",coverURL:"https://cdn.intechopen.com/books/images_new/11430.jpg",subseries:null}}]},overviewPagePublishedBooks:{paginationCount:12,paginationItems:[{type:"book",id:"6692",title:"Medical and Biological Image Analysis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6692.jpg",slug:"medical-and-biological-image-analysis",publishedDate:"July 4th 2018",editedByType:"Edited by",bookSignature:"Robert Koprowski",hash:"e75f234a0fc1988d9816a94e4c724deb",volumeInSeries:1,fullTitle:"Medical and Biological Image Analysis",editors:[{id:"50150",title:"Prof.",name:"Robert",middleName:null,surname:"Koprowski",slug:"robert-koprowski",fullName:"Robert Koprowski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTYNQA4/Profile_Picture_1630478535317",biography:"Robert Koprowski, MD (1997), PhD (2003), Habilitation (2015), is an employee of the University of Silesia, Poland, Institute of Computer Science, Department of Biomedical Computer Systems. For 20 years, he has studied the analysis and processing of biomedical images, emphasizing the full automation of measurement for a large inter-individual variability of patients. Dr. Koprowski has authored more than a hundred research papers with dozens in impact factor (IF) journals and has authored or co-authored six books. Additionally, he is the author of several national and international patents in the field of biomedical devices and imaging. Since 2011, he has been a reviewer of grants and projects (including EU projects) in biomedical engineering.",institutionString:null,institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}]},{type:"book",id:"7218",title:"OCT",subtitle:"Applications in Ophthalmology",coverURL:"https://cdn.intechopen.com/books/images_new/7218.jpg",slug:"oct-applications-in-ophthalmology",publishedDate:"September 19th 2018",editedByType:"Edited by",bookSignature:"Michele Lanza",hash:"e3a3430cdfd6999caccac933e4613885",volumeInSeries:2,fullTitle:"OCT - Applications in Ophthalmology",editors:[{id:"240088",title:"Prof.",name:"Michele",middleName:null,surname:"Lanza",slug:"michele-lanza",fullName:"Michele Lanza",profilePictureURL:"https://mts.intechopen.com/storage/users/240088/images/system/240088.png",biography:"Michele Lanza is Associate Professor of Ophthalmology at Università della Campania, Luigi Vanvitelli, Napoli, Italy. His fields of interest are anterior segment disease, keratoconus, glaucoma, corneal dystrophies, and cataracts. His research topics include\nintraocular lens power calculation, eye modification induced by refractive surgery, glaucoma progression, and validation of new diagnostic devices in ophthalmology. \nHe has published more than 100 papers in international and Italian scientific journals, more than 60 in journals with impact factors, and chapters in international and Italian books. He has also edited two international books and authored more than 150 communications or posters for the most important international and Italian ophthalmology conferences.",institutionString:'University of Campania "Luigi Vanvitelli"',institution:{name:'University of Campania "Luigi Vanvitelli"',institutionURL:null,country:{name:"Italy"}}}]},{type:"book",id:"7560",title:"Non-Invasive Diagnostic Methods",subtitle:"Image Processing",coverURL:"https://cdn.intechopen.com/books/images_new/7560.jpg",slug:"non-invasive-diagnostic-methods-image-processing",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Mariusz Marzec and Robert Koprowski",hash:"d92fd8cf5a90a47f2b8a310837a5600e",volumeInSeries:3,fullTitle:"Non-Invasive Diagnostic Methods - Image Processing",editors:[{id:"253468",title:"Dr.",name:"Mariusz",middleName:null,surname:"Marzec",slug:"mariusz-marzec",fullName:"Mariusz Marzec",profilePictureURL:"https://mts.intechopen.com/storage/users/253468/images/system/253468.png",biography:"An assistant professor at Department of Biomedical Computer Systems, at Institute of Computer Science, Silesian University in Katowice. Scientific interests: computer analysis and processing of images, biomedical images, databases and programming languages. He is an author and co-author of scientific publications covering analysis and processing of biomedical images and development of database systems.",institutionString:"University of Silesia",institution:null}]},{type:"book",id:"6843",title:"Biomechanics",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6843.jpg",slug:"biomechanics",publishedDate:"January 30th 2019",editedByType:"Edited by",bookSignature:"Hadi Mohammadi",hash:"85132976010be1d7f3dbd88662b785e5",volumeInSeries:4,fullTitle:"Biomechanics",editors:[{id:"212432",title:"Prof.",name:"Hadi",middleName:null,surname:"Mohammadi",slug:"hadi-mohammadi",fullName:"Hadi Mohammadi",profilePictureURL:"https://mts.intechopen.com/storage/users/212432/images/system/212432.jpeg",biography:"Dr. Hadi Mohammadi is a biomedical engineer with hands-on experience in the design and development of many engineering structures and medical devices through various projects that he has been involved in over the past twenty years. Dr. Mohammadi received his BSc. and MSc. degrees in Mechanical Engineering from Sharif University of Technology, Tehran, Iran, and his PhD. degree in Biomedical Engineering (biomaterials) from the University of Western Ontario. He was a postdoctoral trainee for almost four years at University of Calgary and Harvard Medical School. He is an industry innovator having created the technology to produce lifelike synthetic platforms that can be used for the simulation of almost all cardiovascular reconstructive surgeries. He’s been heavily involved in the design and development of cardiovascular devices and technology for the past 10 years. He is currently an Assistant Professor with the University of British Colombia, Canada.",institutionString:"University of British Columbia",institution:{name:"University of British Columbia",institutionURL:null,country:{name:"Canada"}}}]}]},openForSubmissionBooks:{paginationCount:3,paginationItems:[{id:"11675",title:"Advances in Skeletal Muscle Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/11675.jpg",hash:"e1d9662c334dd78ab35bfb57c3bf106e",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"April 19th 2022",isOpenForSubmission:!0,editors:[{id:"281317",title:"Dr.",name:"Fabio",surname:"Iannotti",slug:"fabio-iannotti",fullName:"Fabio Iannotti"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11677",title:"New Insights in Mammalian Endocrinology",coverURL:"https://cdn.intechopen.com/books/images_new/11677.jpg",hash:"c59dd0f87bbf829ca091c485f4cc4e68",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"May 5th 2022",isOpenForSubmission:!0,editors:[{id:"321396",title:"Prof.",name:"Muhammad Subhan",surname:"Qureshi",slug:"muhammad-subhan-qureshi",fullName:"Muhammad Subhan Qureshi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11676",title:"Recent Advances in Homeostasis",coverURL:"https://cdn.intechopen.com/books/images_new/11676.jpg",hash:"63eb775115bf2d6d88530b234a1cc4c2",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"June 10th 2022",isOpenForSubmission:!0,editors:[{id:"203015",title:"Dr.",name:"Gaffar",surname:"Zaman",slug:"gaffar-zaman",fullName:"Gaffar Zaman"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{paginationCount:49,paginationItems:[{id:"80495",title:"Iron in Cell Metabolism and Disease",doi:"10.5772/intechopen.101908",signatures:"Eeka Prabhakar",slug:"iron-in-cell-metabolism-and-disease",totalDownloads:2,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81799",title:"Cross Talk of Purinergic and Immune Signaling: Implication in Inflammatory and Pathogenic Diseases",doi:"10.5772/intechopen.104978",signatures:"Richa Rai",slug:"cross-talk-of-purinergic-and-immune-signaling-implication-in-inflammatory-and-pathogenic-diseases",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81764",title:"Involvement of the Purinergic System in Cell Death in Models of Retinopathies",doi:"10.5772/intechopen.103935",signatures:"Douglas Penaforte Cruz, Marinna Garcia Repossi and Lucianne Fragel Madeira",slug:"involvement-of-the-purinergic-system-in-cell-death-in-models-of-retinopathies",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81756",title:"Alteration of Cytokines Level and Oxidative Stress Parameters in COVID-19",doi:"10.5772/intechopen.104950",signatures:"Marija Petrusevska, Emilija Atanasovska, Dragica Zendelovska, Aleksandar Eftimov and Katerina Spasovska",slug:"alteration-of-cytokines-level-and-oxidative-stress-parameters-in-covid-19",totalDownloads:9,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Chemokines Updates",coverURL:"https://cdn.intechopen.com/books/images_new/11672.jpg",subseries:{id:"18",title:"Proteomics"}}},{id:"81681",title:"Immunomodulatory Effects of a M2-Conditioned Medium (PRS® CK STORM): Theory on the Possible Complex Mechanism of Action through Anti-Inflammatory Modulation of the TLR System and the Purinergic System",doi:"10.5772/intechopen.104486",signatures:"Juan Pedro Lapuente",slug:"immunomodulatory-effects-of-a-m2-conditioned-medium-prs-ck-storm-theory-on-the-possible-complex-mech",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81647",title:"Diabetes and Epigenetics",doi:"10.5772/intechopen.104653",signatures:"Rasha A. Alhazzaa, Thomas Heinbockel and Antonei B. Csoka",slug:"diabetes-and-epigenetics",totalDownloads:10,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"81580",title:"Graft-Versus-Host Disease: Pathogenesis and Treatment",doi:"10.5772/intechopen.104450",signatures:"Shin Mukai",slug:"graft-versus-host-disease-pathogenesis-and-treatment",totalDownloads:14,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81533",title:"Prenylation of Natural Products: An Overview",doi:"10.5772/intechopen.104636",signatures:"Kantharaju Kamanna and Aravind Kamath",slug:"prenylation-of-natural-products-an-overview",totalDownloads:19,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Kantharaju",surname:"Kamanna"}],book:{title:"Modifications of Biomolecules",coverURL:"https://cdn.intechopen.com/books/images_new/11098.jpg",subseries:null}},{id:"81067",title:"Encapsulation of Essential Oils and Their Use in Food Applications",doi:"10.5772/intechopen.103147",signatures:"Hamdy A. Shaaban and Amr Farouk",slug:"encapsulation-of-essential-oils-and-their-use-in-food-applications",totalDownloads:47,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Essential Oils - Advances in Extractions and Biological Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",subseries:{id:"15",title:"Chemical Biology"}}},{id:"81099",title:"SK Channels and Heart Disease",doi:"10.5772/intechopen.104115",signatures:"Katherine Zhong, Shawn Kant, Frank Sellke and Jun Feng",slug:"sk-channels-and-heart-disease",totalDownloads:16,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}}]},subseriesFiltersForOFChapters:[{caption:"Proteomics",value:18,count:3,group:"subseries"},{caption:"Metabolism",value:17,count:9,group:"subseries"},{caption:"Cell and Molecular Biology",value:14,count:17,group:"subseries"},{caption:"Chemical Biology",value:15,count:19,group:"subseries"}],publishedBooks:{paginationCount:27,paginationItems:[{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",slug:"reactive-oxygen-species",publishedDate:"April 28th 2022",editedByType:"Edited by",bookSignature:"Rizwan Ahmad",hash:"176adcf090fdd1f93cb8ce3146e79ca1",volumeInSeries:28,fullTitle:"Reactive Oxygen Species",editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad",profilePictureURL:"https://mts.intechopen.com/storage/users/40482/images/system/40482.jpeg",institutionString:"Imam Abdulrahman Bin Faisal University",institution:{name:"Imam Abdulrahman Bin Faisal University",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9008",title:"Vitamin K",subtitle:"Recent Topics on the Biology and Chemistry",coverURL:"https://cdn.intechopen.com/books/images_new/9008.jpg",slug:"vitamin-k-recent-topics-on-the-biology-and-chemistry",publishedDate:"March 23rd 2022",editedByType:"Edited by",bookSignature:"Hiroyuki Kagechika and Hitoshi Shirakawa",hash:"8b43add5389ba85743e0a9491e4b9943",volumeInSeries:27,fullTitle:"Vitamin K - Recent Topics on the Biology and Chemistry",editors:[{id:"180528",title:"Dr.",name:"Hiroyuki",middleName:null,surname:"Kagechika",slug:"hiroyuki-kagechika",fullName:"Hiroyuki Kagechika",profilePictureURL:"https://mts.intechopen.com/storage/users/180528/images/system/180528.jpg",institutionString:"Tokyo Medical and Dental University",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10799",title:"Phenolic Compounds",subtitle:"Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10799.jpg",slug:"phenolic-compounds-chemistry-synthesis-diversity-non-conventional-industrial-pharmaceutical-and-therapeutic-applications",publishedDate:"February 23rd 2022",editedByType:"Edited by",bookSignature:"Farid A. Badria",hash:"339199f254d2987ef3167eef74fb8a38",volumeInSeries:26,fullTitle:"Phenolic Compounds - Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria",profilePictureURL:"https://mts.intechopen.com/storage/users/41865/images/system/41865.jpg",institutionString:"Mansoura University",institution:{name:"Mansoura University",institutionURL:null,country:{name:"Egypt"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9659",title:"Fibroblasts",subtitle:"Advances in Inflammation, Autoimmunity and Cancer",coverURL:"https://cdn.intechopen.com/books/images_new/9659.jpg",slug:"fibroblasts-advances-in-inflammation-autoimmunity-and-cancer",publishedDate:"December 22nd 2021",editedByType:"Edited by",bookSignature:"Mojca Frank Bertoncelj and Katja Lakota",hash:"926fa6446f6befbd363fc74971a56de2",volumeInSeries:25,fullTitle:"Fibroblasts - Advances in Inflammation, Autoimmunity and Cancer",editors:[{id:"328755",title:"Ph.D.",name:"Mojca",middleName:null,surname:"Frank Bertoncelj",slug:"mojca-frank-bertoncelj",fullName:"Mojca Frank Bertoncelj",profilePictureURL:"https://mts.intechopen.com/storage/users/328755/images/system/328755.jpg",institutionString:"BioMed X Institute",institution:{name:"University Hospital of Zurich",institutionURL:null,country:{name:"Switzerland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8977",title:"Protein Kinases",subtitle:"Promising Targets for Anticancer Drug Research",coverURL:"https://cdn.intechopen.com/books/images_new/8977.jpg",slug:"protein-kinases-promising-targets-for-anticancer-drug-research",publishedDate:"December 8th 2021",editedByType:"Edited by",bookSignature:"Rajesh Kumar Singh",hash:"6d200cc031706a565b554fdb1c478901",volumeInSeries:24,fullTitle:"Protein Kinases - Promising Targets for Anticancer Drug Research",editors:[{id:"329385",title:"Dr.",name:"Rajesh K.",middleName:"Kumar",surname:"Singh",slug:"rajesh-k.-singh",fullName:"Rajesh K. Singh",profilePictureURL:"https://mts.intechopen.com/storage/users/329385/images/system/329385.png",institutionString:"Punjab Technical University",institution:{name:"Punjab Technical University",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8018",title:"Extracellular Matrix",subtitle:"Developments and Therapeutics",coverURL:"https://cdn.intechopen.com/books/images_new/8018.jpg",slug:"extracellular-matrix-developments-and-therapeutics",publishedDate:"October 27th 2021",editedByType:"Edited by",bookSignature:"Rama Sashank Madhurapantula, Joseph Orgel P.R.O. and Zvi Loewy",hash:"c85e82851e80b40282ff9be99ddf2046",volumeInSeries:23,fullTitle:"Extracellular Matrix - Developments and Therapeutics",editors:[{id:"212416",title:"Dr.",name:"Rama Sashank",middleName:null,surname:"Madhurapantula",slug:"rama-sashank-madhurapantula",fullName:"Rama Sashank Madhurapantula",profilePictureURL:"https://mts.intechopen.com/storage/users/212416/images/system/212416.jpg",institutionString:"Illinois Institute of Technology",institution:{name:"Illinois Institute of Technology",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9759",title:"Vitamin E in Health and Disease",subtitle:"Interactions, Diseases and Health Aspects",coverURL:"https://cdn.intechopen.com/books/images_new/9759.jpg",slug:"vitamin-e-in-health-and-disease-interactions-diseases-and-health-aspects",publishedDate:"October 6th 2021",editedByType:"Edited by",bookSignature:"Pınar Erkekoglu and Júlia Scherer Santos",hash:"6c3ddcc13626110de289b57f2516ac8f",volumeInSeries:22,fullTitle:"Vitamin E in Health and Disease - Interactions, Diseases and Health Aspects",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoğlu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoğlu",profilePictureURL:"https://mts.intechopen.com/storage/users/109978/images/system/109978.jpg",institutionString:"Hacettepe University",institution:{name:"Hacettepe University",institutionURL:null,country:{name:"Turkey"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9753",title:"Terpenes and Terpenoids",subtitle:"Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/9753.jpg",slug:"terpenes-and-terpenoids-recent-advances",publishedDate:"July 28th 2021",editedByType:"Edited by",bookSignature:"Shagufta Perveen and Areej Mohammad Al-Taweel",hash:"575689df13c78bf0e6c1be40804cd010",volumeInSeries:21,fullTitle:"Terpenes and Terpenoids - Recent Advances",editors:[{id:"192992",title:"Prof.",name:"Shagufta",middleName:null,surname:"Perveen",slug:"shagufta-perveen",fullName:"Shagufta Perveen",profilePictureURL:"https://mts.intechopen.com/storage/users/192992/images/system/192992.png",institutionString:"King Saud University",institution:{name:"King Saud University",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9403",title:"Human Microbiome",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9403.jpg",slug:"human-microbiome",publishedDate:"June 16th 2021",editedByType:"Edited by",bookSignature:"Natalia V. Beloborodova and Andrey V. Grechko",hash:"c31366ba82585ba3ac91d21eb1cf0a4d",volumeInSeries:20,fullTitle:"Human Microbiome",editors:[{id:"199461",title:"Prof.",name:"Natalia V.",middleName:null,surname:"Beloborodova",slug:"natalia-v.-beloborodova",fullName:"Natalia V. Beloborodova",profilePictureURL:"https://mts.intechopen.com/storage/users/199461/images/system/199461.jpg",institutionString:"Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",slug:"oxidoreductase",publishedDate:"February 17th 2021",editedByType:"Edited by",bookSignature:"Mahmoud Ahmed Mansour",hash:"852e6f862c85fc3adecdbaf822e64e6e",volumeInSeries:19,fullTitle:"Oxidoreductase",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour",profilePictureURL:"https://mts.intechopen.com/storage/users/224662/images/system/224662.jpg",institutionString:"King Saud bin Abdulaziz University for Health Sciences",institution:{name:"King Saud bin Abdulaziz University for Health Sciences",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9742",title:"Ubiquitin",subtitle:"Proteasome Pathway",coverURL:"https://cdn.intechopen.com/books/images_new/9742.jpg",slug:"ubiquitin-proteasome-pathway",publishedDate:"December 9th 2020",editedByType:"Edited by",bookSignature:"Xianquan Zhan",hash:"af6880d3a5571da1377ac8f6373b9e82",volumeInSeries:18,fullTitle:"Ubiquitin - Proteasome Pathway",editors:[{id:"223233",title:"Prof.",name:"Xianquan",middleName:null,surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan",profilePictureURL:"https://mts.intechopen.com/storage/users/223233/images/system/223233.png",institutionString:"Shandong First Medical University",institution:{name:"Affiliated Hospital of Shandong Academy of Medical Sciences",institutionURL:null,country:{name:"China"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9002",title:"Glutathione System and Oxidative Stress in Health and Disease",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9002.jpg",slug:"glutathione-system-and-oxidative-stress-in-health-and-disease",publishedDate:"August 26th 2020",editedByType:"Edited by",bookSignature:"Margarete Dulce Bagatini",hash:"127defed0a50ad5ed92338dc96e1e10e",volumeInSeries:17,fullTitle:"Glutathione System and Oxidative Stress in Health and Disease",editors:[{id:"217850",title:"Dr.",name:"Margarete Dulce",middleName:null,surname:"Bagatini",slug:"margarete-dulce-bagatini",fullName:"Margarete Dulce Bagatini",profilePictureURL:"https://mts.intechopen.com/storage/users/217850/images/system/217850.jpeg",institutionString:"Universidade Federal da Fronteira Sul",institution:{name:"Universidade Federal da Fronteira Sul",institutionURL:null,country:{name:"Brazil"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Proteomics",value:18,count:3},{group:"subseries",caption:"Metabolism",value:17,count:6},{group:"subseries",caption:"Cell and Molecular Biology",value:14,count:8},{group:"subseries",caption:"Chemical Biology",value:15,count:10}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:3},{group:"publicationYear",caption:"2021",value:2021,count:7},{group:"publicationYear",caption:"2020",value:2020,count:12},{group:"publicationYear",caption:"2019",value:2019,count:3},{group:"publicationYear",caption:"2018",value:2018,count:2}],authors:{}},subseries:{item:{id:"27",type:"subseries",title:"Multi-Agent Systems",keywords:"Collaborative Intelligence, Learning, Distributed Control System, Swarm Robotics, Decision Science, Software Engineering",scope:"Multi-agent systems are recognised as a state of the art field in Artificial Intelligence studies, which is popular due to the usefulness in facilitation capabilities to handle real-world problem-solving in a distributed fashion. The area covers many techniques that offer solutions to emerging problems in robotics and enterprise-level software systems. Collaborative intelligence is highly and effectively achieved with multi-agent systems. Areas of application include swarms of robots, flocks of UAVs, collaborative software management. Given the level of technological enhancements, the popularity of machine learning in use has opened a new chapter in multi-agent studies alongside the practical challenges and long-lasting collaboration issues in the field. It has increased the urgency and the need for further studies in this field. We welcome chapters presenting research on the many applications of multi-agent studies including, but not limited to, the following key areas: machine learning for multi-agent systems; modeling swarms robots and flocks of UAVs with multi-agent systems; decision science and multi-agent systems; software engineering for and with multi-agent systems; tools and technologies of multi-agent systems.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/27.jpg",hasOnlineFirst:!1,hasPublishedBooks:!1,annualVolume:11423,editor:{id:"148497",title:"Dr.",name:"Mehmet",middleName:"Emin",surname:"Aydin",slug:"mehmet-aydin",fullName:"Mehmet Aydin",profilePictureURL:"https://mts.intechopen.com/storage/users/148497/images/system/148497.jpg",biography:"Dr. Mehmet Emin Aydin is a Senior Lecturer with the Department of Computer Science and Creative Technology, the University of the West of England, Bristol, UK. His research interests include swarm intelligence, parallel and distributed metaheuristics, machine learning, intelligent agents and multi-agent systems, resource planning, scheduling and optimization, combinatorial optimization. Dr. Aydin is currently a Fellow of Higher Education Academy, UK, a member of EPSRC College, a senior member of IEEE and a senior member of ACM. In addition to being a member of advisory committees of many international conferences, he is an Editorial Board Member of various peer-reviewed international journals. He has served as guest editor for a number of special issues of peer-reviewed international journals.",institutionString:null,institution:{name:"University of the West of England",institutionURL:null,country:{name:"United Kingdom"}}},editorTwo:null,editorThree:null,series:{id:"14",title:"Artificial Intelligence",doi:"10.5772/intechopen.79920",issn:"2633-1403"},editorialBoard:[{id:"275140",title:"Dr.",name:"Dinh Hoa",middleName:null,surname:"Nguyen",slug:"dinh-hoa-nguyen",fullName:"Dinh Hoa Nguyen",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRbnKQAS/Profile_Picture_1622204093453",institutionString:null,institution:{name:"Kyushu University",institutionURL:null,country:{name:"Japan"}}},{id:"20259",title:"Dr.",name:"Hongbin",middleName:null,surname:"Ma",slug:"hongbin-ma",fullName:"Hongbin Ma",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRhDJQA0/Profile_Picture_2022-05-02T08:25:21.jpg",institutionString:null,institution:{name:"Beijing Institute of Technology",institutionURL:null,country:{name:"China"}}},{id:"28640",title:"Prof.",name:"Yasushi",middleName:null,surname:"Kambayashi",slug:"yasushi-kambayashi",fullName:"Yasushi Kambayashi",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYOQxQAO/Profile_Picture_1625660525470",institutionString:null,institution:{name:"Nippon Institute of Technology",institutionURL:null,country:{name:"Japan"}}}]},onlineFirstChapters:{paginationCount:13,paginationItems:[{id:"81751",title:"NanoBioSensors: From Electrochemical Sensors Improvement to Theranostic Applications",doi:"10.5772/intechopen.102552",signatures:"Anielle C.A. Silva, Eliete A. Alvin, Lais S. de Jesus, Caio C.L. de França, Marílya P.G. da Silva, Samaysa L. Lins, Diógenes Meneses, Marcela R. Lemes, Rhanoica O. Guerra, Marcos V. da Silva, Carlo J.F. de Oliveira, Virmondes Rodrigues Junior, Renata M. Etchebehere, Fabiane C. de Abreu, Bruno G. Lucca, Sanívia A.L. Pereira, Rodrigo C. Rosa and Noelio O. Dantas",slug:"nanobiosensors-from-electrochemical-sensors-improvement-to-theranostic-applications",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81678",title:"Developmental Studies on Practical Enzymatic Phosphate Ion Biosensors and Microbial BOD Biosensors, and New Insights into the Future Perspectives of These Biosensor Fields",doi:"10.5772/intechopen.104377",signatures:"Hideaki Nakamura",slug:"developmental-studies-on-practical-enzymatic-phosphate-ion-biosensors-and-microbial-bod-biosensors-a",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Hideaki",surname:"Nakamura"}],book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81412",title:"Mathematical Morphology and the Heart Signals",doi:"10.5772/intechopen.104113",signatures:"Taouli Sidi Ahmed",slug:"mathematical-morphology-and-the-heart-signals",totalDownloads:17,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81360",title:"Deep Learning Algorithms for Efficient Analysis of ECG Signals to Detect Heart Disorders",doi:"10.5772/intechopen.103075",signatures:"Sumagna Dey, Rohan Pal and Saptarshi Biswas",slug:"deep-learning-algorithms-for-efficient-analysis-of-ecg-signals-to-detect-heart-disorders",totalDownloads:31,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81068",title:"Characteristic Profiles of Heart Rate Variability in Depression and Anxiety",doi:"10.5772/intechopen.104205",signatures:"Toshikazu Shinba",slug:"characteristic-profiles-of-heart-rate-variability-in-depression-and-anxiety",totalDownloads:20,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"80691",title:"Applications of Quantum Mechanics, Laws of Classical Physics, and Differential Calculus to Evaluate Source Localization According to the Electroencephalogram",doi:"10.5772/intechopen.102831",signatures:"Kristin S. Williams",slug:"applications-of-quantum-mechanics-laws-of-classical-physics-and-differential-calculus-to-evaluate-so",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"80643",title:"EEG Authentication System Using Fuzzy Vault Scheme",doi:"10.5772/intechopen.102699",signatures:"Fatima M. Baqer and Salah Albermany",slug:"eeg-authentication-system-using-fuzzy-vault-scheme",totalDownloads:34,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"80529",title:"Effective EEG Artifact Removal from EEG Signal",doi:"10.5772/intechopen.102698",signatures:"Vandana Roy",slug:"effective-eeg-artifact-removal-from-eeg-signal",totalDownloads:66,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"80505",title:"Soft Tissue Image Reconstruction Using Diffuse Optical Tomography",doi:"10.5772/intechopen.102463",signatures:"Umamaheswari K, Shrichandran G.V. and Jebaderwin D.",slug:"soft-tissue-image-reconstruction-using-diffuse-optical-tomography",totalDownloads:47,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"79881",title:"Control of Cytoskeletal Dynamics in Cancer through a Combination of Cytoskeletal Components",doi:"10.5772/intechopen.101624",signatures:"Ban Hussein Alwash, Rawan Asaad Jaber Al-Rubaye, Mustafa Mohammad Alaaraj and Anwar Yahya Ebrahim",slug:"control-of-cytoskeletal-dynamics-in-cancer-through-a-combination-of-cytoskeletal-components",totalDownloads:104,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Cancer Bioinformatics",coverURL:"https://cdn.intechopen.com/books/images_new/10661.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"79580",title:"Dotting the “i” of Interoperability in FAIR Cancer-Registry Data Sets",doi:"10.5772/intechopen.101330",signatures:"Nicholas Nicholson, Francesco Giusti, Luciana Neamtiu, Giorgia Randi, Tadeusz Dyba, Manola Bettio, Raquel Negrao Carvalho, Nadya Dimitrova, Manuela Flego and Carmen Martos",slug:"dotting-the-i-of-interoperability-in-fair-cancer-registry-data-sets",totalDownloads:100,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Cancer Bioinformatics",coverURL:"https://cdn.intechopen.com/books/images_new/10661.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"79550",title:"Urologic Cancer Molecular Biology",doi:"10.5772/intechopen.101381",signatures:"Pavel Onofrei, Viorel Dragoș Radu, Alina-Alexandra Onofrei, Stoica Laura, Doinita Temelie-Olinici, Ana-Emanuela Botez, Vasile Bogdan Grecu and Elena Carmen Cotrutz",slug:"urologic-cancer-molecular-biology",totalDownloads:96,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Cancer Bioinformatics",coverURL:"https://cdn.intechopen.com/books/images_new/10661.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"79450",title:"Identification of Biomarkers Associated with Cancer Using Integrated Bioinformatic Analysis",doi:"10.5772/intechopen.101432",signatures:"Arpana Parihar, Shivani Malviya and Raju Khan",slug:"identification-of-biomarkers-associated-with-cancer-using-integrated-bioinformatic-analysis",totalDownloads:156,totalCrossrefCites:1,totalDimensionsCites:1,authors:null,book:{title:"Cancer Bioinformatics",coverURL:"https://cdn.intechopen.com/books/images_new/10661.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}}]},publishedBooks:{},testimonialsList:[{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.jpg",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[],lsSeriesList:[],hsSeriesList:[],sshSeriesList:[],subseriesList:[],annualVolumeBook:{},thematicCollection:[],selectedSeries:null,selectedSubseries:null},seriesLanding:{item:null},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"chapter.detail",path:"/chapters/36789",hash:"",query:{},params:{id:"36789"},fullPath:"/chapters/36789",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()